

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

**(19) World Intellectual Property Organization
International Bureau**



A standard linear barcode is located at the bottom of the page, spanning most of the width.

(43) International Publication Date
20 December 2001 (20.12.2001)

PCT

(10) International Publication Number
WO 01/096311 A3

- (51) International Patent Classification⁷: C07D 221/06, 221/16, 221/18, A61P 3/06, A61K 31/435

(21) International Application Number: PCT/US01/18868

(22) International Filing Date: 12 June 2001 (12.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/211,594 15 June 2000 (15.06.2000) US

(71) Applicant (for all designated States except US): BRISTOL-MYERS SQUIBB COMPANY [US/US]; P.O. Box 4000, Princeton, NJ 08543-4000 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ROBL, Jeffrey, A. [US/US]; 7 Tulip Drive, Newtown, PA 18940 (US). CHEN, Bang-Chi [CN/US]; 28 Marion Drive, Plainsboro, NJ 18940 (US). SUN, Chong-Qing [CN/US]; 527 Dutch Neck Road, East Windsor, NJ 08520 (US).

(74) Agents: RODNEY, Burten et al.; Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543-4000 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

 - with international search report
 - before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report: 11 July 2002



Published:

- with international search report
 - before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

(88) Date of publication of the international search report:
11 July 2002

[Continued on next page]

(54) Title: HMG-COA REDUCTASE INHIBITORS AND THEIR USE AS MEDICAMENTS FOR THE TREATMENT OF CHOLESTEROL RELATED DISEASES



(57) Abstract: Compounds of the following structure are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia, dyslipidemia, hormone replacement therapy, hypercholesterolemia, hypertriglyceridemia and atherosclerosis as well as Alzheimer's disease and osteoporosis (Formula (I)) and pharmaceutically acceptable salts thereof. Z is Formula (a) or Formula (b); n is 0 or 1; x is 0, 1, 2, 3 or 4; y is 0, 1, 2, 3 or 4, provided that at least one of x and y is other than 0; and optionally one or more carbons of $(\text{CH}_2)_x$ and/or $(\text{CH}_2)_y$, together with additional carbons form a 3 to 7 membered spirocyclic ring; R₁ and R₂ are the same or different and are independently selected from alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl or cycloheteroalkyl; R₃ is H or lower alkyl; R₄ and R₅ are as defined herein.

WO 01/096311 A3



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

Int. Jnl Application No
PCT/US 01/18868

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D221/06 C07D221/16 C07D221/18 A61P3/06 A61K31/435

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, EPO-Internal, PAJ, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>CHEMICAL ABSTRACTS, vol. 114, no. 27, 18 February 1991 (1991-02-18) Columbus, Ohio, US; abstract no. 61895q, SLISKOV: page 669; column 2; XP002196157 abstract & SLISKOVIC, D. R. ET AL.: "Inhibitors of cholesterol biosynthesis. 4. trans-6-'2-(substituted-quinolinyl)ethenyl /ethyl!tetrahydro-4-hydroxy-2H-pyran-2-one s, a novel series of HMG-CoA reductase inhibitors" JOURNAL OF MEDICINAL CHEMISTRY., vol. 34, no. 1, 1991, pages 367-373, AMERICAN CHEMICAL SOCIETY., US ISSN: 0022-2623</p> <p>---</p> <p>-/-</p>	1-18

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *8* document member of the same patent family

Date of the actual completion of the international search

15 April 2002

Date of mailing of the international search report

03/05/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Hoepfner, W

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 01/18868

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 686 433 A (ROBL JEFFREY ADAM) 11 November 1997 (1997-11-11) cited in the application column 1, line 18 - line 28 column 6, formula 5 in connection with columns 7-10, Scheme 3 -----	1-18

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/US 01/18868

Patent document cited in search report	Publication date		Patent family member(s)		Publication date
US 5686433	A	11-11-1997	US 5506219 A		09-04-1996
			US 5691322 A		25-11-1997
			AU 645287 B2		13-01-1994
			AU 7101691 A		29-08-1991
			CA 2036417 A1		27-08-1991
			EP 0444533 A2		04-09-1991
			HU 56574 A2		30-09-1991
			IE 910543 A1		28-08-1991
			JP 4211660 A		03-08-1992
			NZ 237097 A		23-12-1993
			PT 96874 A		31-10-1991
			ZA 9101046 A		28-10-1992
			AU 637321 B2		27-05-1993
			AU 3941389 A		21-06-1990
			DK 422989 A		01-03-1990
			EP 0356788 A2		07-03-1990
			HU 52479 A2		28-07-1990
			JP 2108665 A		20-04-1990
			NZ 230121 A		26-08-1993
			ZA 8905869 A		30-05-1990

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 December 2001 (20.12.2001)

PCT

(10) International Publication Number
WO 01/96311 A2

(51) International Patent Classification⁷: C07D 221/06

(74) Agents: RODNEY, Burten et al.; Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543-4000 (US).

(21) International Application Number: PCT/US01/18868

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 12 June 2001 (12.06.2001)

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: English

Published:

(26) Publication Language: English

— without international search report and to be republished upon receipt of that report

(30) Priority Data:
60/211,594 15 June 2000 (15.06.2000) US




(71) Applicant (for all designated States except US): BRISTOL-MYERS SQUIBB COMPANY [US/US]; P.O. Box 4000, Princeton, NJ 08543-4000 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ROBL, Jeffrey, A. [US/US]; 7 Tulip Drive, Newtown, PA 18940 (US). CHEN, Bang-Chi [CN/US]; 28 Marion Drive, Plainsboro, NJ 18940 (US). SUN, Chong-Qing [CN/US]; 527 Dutch Neck Road, East Windsor, NJ 08520 (US).

[Continued on next page]

(54) Title: HMG-CoA REDUCTASE INHIBITORS AND METHOD



A2
WO 01/96311

(57) Abstract: Compounds of the following structure are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia, dyslipidemia, hormone replacement therapy, hypercholesterolemia, hypertriglyceridemia and atherosclerosis as well as Alzheimer's disease and osteoporosis (Formula (I)) and pharmaceutically acceptable salts thereof, Z is Formula (a) or Formula (b); n is 0 or 1; x is 0, 1, 2, 3 or 4; y is 0, 1, 2, 3 or 4, provided that at least one of x and y is other than 0; and optionally one or more carbons of (CH₂)_x and/or (CH₂)_y, together with additional carbons form a 3 to 7 membered spirocyclic ring; R₁ and R₂ are the same or different and are independently selected from alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl or cycloheteroalkyl; R₃ is H or lower alkyl; R₄ and R₇ are as defined herein.

WO 01/96311 A2




For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

HMG-CoA REDUCTASE INHIBITORS AND METHOD

5 The present invention relates to compounds and pharmaceutical compositions useful as hypocholesterolemic and hypolipidemic agents. More particularly, this invention concerns (1) certain inhibitors of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA
 10 reductase) that include a pyridine containing nucleus attached by means of a linker to an HMG-binding domain sidechain, (2) pharmaceutical compositions containing such compounds and (3) a method of lowering blood serum cholesterol levels and modulating blood serum lipids
 15 employing such pharmaceutical compositions.

U.S. Patent No. 5,686,433 to Robl discloses the structure



20 wherein:

Am is a binding domain sidechain;

X is a linker;

R¹ and R² are the same or different and are each independently selected from

- 25 (i) hydrogen,
 (ii) alkyl,
 (iii) aryl,

- (iv) cycloalkyl,
(v) aralkyl,
(vi) aralkoxy,
5 (vii) alkenyl,
(viii) cycloalkenyl, and
(ix) heterocyclo (e.g., thienyl, benzodioxolyl);


R^3 is selected from

- 10 (i) hydrogen,
(ii) lower alkyl,
(iii) aryl,
(iv) cycloalkyl,
(v) alkoxy,
15 (vi) aralkyl,
(vii) aralkoxy,
(viii) alkenyl,
(ix) cycloalkenyl,
(x) halo-substituted alkyl,
20 (xi) adamantyl, and
(xii) heterocyclo (e.g., thienyl, benzodioxolyl);


R^4 is selected from

- 25 (i) hydrogen,
(ii) lower alkyl,
(iii) aryl,
(iv) cycloalkyl,
(v) alkoxy,
(vi) aralkyl,
30 (vii) aralkoxy,
(viii) alkenyl,
(ix) cycloalkenyl,
(x) adamantyl,
(xi) halogen,
35 (xii) halo-substituted alkyl (e.g., trifluoromethyl), and

(xiii) heterocyclo (e.g., thienyl, benzodioxolyl);
or R³ and R⁴ taken together can be



5 but when A_m is



or a δ lactone thereof, R³ and R⁴ cannot be $(CH=CH)_2$;

R⁶ is hydrogen or lower alkyl;

R⁸ is hydrogen, lower alkyl, alkali metal, or

10 alkaline earth metal;

n is 0 or 1;

p is 3, 4 or 5;


q is 0, 1, 2, or 3; and

r is 0, 1, 2, or 3.

15 In preferred embodiments (A_m) is an HMG-binding domain sidechain having a dihydroxy or a phosphinic acid function.


The phosphinic (or phosphonic when X is CH₂-O-) acid HMG-binding domain sidechain (A₁) is

20




wherein R⁵ and R⁷ are independently selected from hydrogen, lower alkyl, alkali metal ion and alkaline earth metal ion; and R⁶ is hydrogen or lower alkyl.

25 The dihydroxy acid binding domain sidechain (A₂) is



wherein R⁶ is hydrogen or lower alkyl, R⁸ is hydrogen or lower alkyl in free acid form or in the form of a

physiologically acceptable and hydrolyzable ester or δ lactone thereof (i.e., when Am is




- 5 In addition, R⁸ can be alkali metal ion or alkaline earth metal ion.

A suitable linker (X) is -(CH₂)_a- , -CH=CH-, -C≡C-, -CH₂O-, wherein O is linked to the phosphorous atom or the aromatic anchor when Am is A₁, and wherein O is
10 linked to the aromatic anchor when Am is A₂, and wherein "a" is 1, 2, or 3.


In accordance with the present invention, there are provided certain pyridine-containing compounds that are
15 potent inhibitors of cholesterol biosynthesis by virtue of their ability to inhibit the enzyme 3-methyl-glutaryl-coenzyme A reductase (HMG-CoA reductase).

In particular, in its broadest chemical compound aspect, the present invention provides compounds of the
20 formula

I



wherein



n is 0 or 1;

x is 0, 1, 2, 3 or 4;

y is 0, 1, 2, 3 or 4, provided that at least one of
5 x and y is other than o;

and optionally one or more carbons of (CH₂)_x and/or
(CH₂)_y may form part of a 3 to 7 membered spirocyclic
ring;

10 R₁ and R₂ are the same or different and are
independently selected from alkyl, arylalkyl, cycloalkyl,
alkenyl, cycloalkenyl, aryl, heteroaryl or
cycloheteroalkyl;

R₃ is H or lower alkyl;

15 R₄ is H, halogen, CF₃, hydroxy, alkyl, alkoxy,
alkanoylamino, aroylamino or cyano;

R₇ is H or lower alkyl;

and \swarrow represents a single bond or a double bond
(which may be cis or trans);

20 and including pharmaceutically acceptable salts
thereof when R₃ is H, esters thereof, prodrug esters
thereof, and all stereoisomers thereof.

Preferably, the Z group will be in form of a free
acid, a physiologically acceptable and hydrolyzable ester
or δ lactone thereof, or an alkali metal salt, alkaline
25 earth metal salt or an amino acid salt.

Preferred are compounds of formula I of the
invention wherein

R₁ and R₂ are independently selected from alkyl,
cycloalkyl and aryl;

30 R₄ is H, alkyl, or halogen;
x is 2 or 3;
y is o; and
n is o.

More preferred are compounds of formula I of the invention wherein R₁ is aryl (especially substituted aryl as defined hereinafter);

R₂ is alkyl or cycloalkyl;

5 R₄ is H;

x is 3;

y is o;

n is o; and

~~=~~ is a double bond.

10 Still more preferred are compounds of formula I of the invention wherein

R₁ is substituted aryl, preferably 4-fluorophenyl, 4-fluoro-3-methylphenyl or 3,5-dimethylphenyl;

15 R₂ is alkyl or cycloalkyl, preferably isopropyl, t-butyl or cyclopropyl;


R₄ is H;

x is 3;

y is o;

n is o;


20 ~~=~~ is a double bond, preferably "trans"; and



or an alkali metal salt thereof, alkaline earth metal salt or an amino acid salt.

25 Most preferred compounds of formula I of the invention will have the structure IA

IA



or an alkali or alkaline earth metal (such as Na, K or Ca) salt thereof, or amino acid salt (such as arginine), wherein R₅ and R₆ are the same or different and independently selected from H, halogen and/or alkyl (preferably 4-fluoro, 4-fluoro-3-methyl or 3,5-dimethyl); and

R₂ is alkyl or cycloalkyl, preferably isopropyl, t-butyl or cyclopropyl.

In another aspect, the present invention provides pharmaceutical compositions, useful as hypolipidemic or hypocholesterolemic agents, or hypotriglyceridemic agents, or anti-Alzheimer's agents, or anti-osteoporosis agents as well as other uses as described herein, comprising a hypolipidemic or hypocholesterolemic or hypotriglyceridemic or anti-Alzheimer's disease or anti-osteoporosis amount, or other therapeutically effective amount (depending upon use) of a compound of formula I in accordance with this invention, in combination with a pharmaceutically acceptable carrier.

In another aspect, the present invention provides a method of inhibiting cholesterol biosynthesis or lowering blood serum cholesterol levels and/or modulating blood serum cholesterol levels such as lowering LDL cholesterol and/or increasing HDL cholesterol, or treating dyslipidemia, mixed dyslipidemia, hyperlipidemia, hypercholesterolemia, hypo α-lipoproteinemia, LDL Pattern B, LDL Pattern A, hyperlipoproteinemia or hypertriglyceridemia, and other aberrations of apolipoprotein B metabolism, or reducing levels of Lp(a), or treating or preventing other cholesterol-related diseases, or treating or preventing or reversing progression of atherosclerosis, or preventing or treating Alzheimer's disease, or preventing or treating osteoporosis and/or osteopenia, or reducing inflammatory markers such as C-reactive protein, or preventing or treating low grade vascular inflammation, or preventing or treating stroke, or preventing or treating dementia,

or preventing and treating coronary heart disease (including primary and secondary prevention of myocardial infarction), or preventing or treating stable and unstable angina, or primary prevention of coronary 5 events, or secondary prevention of cardiovascular events, or preventing or treating peripheral vascular disease, preventing or treating peripheral arterial disease, or preventing or treating acute vascular syndromes, or preventing or reducing the risk of undergoing myocardial 10 revascularization procedures, or preventing or treating microvascular diseases such as nephropathy, neuropathy, retinopathy and nephrotic syndrome or preventing or treating hypertension in a patient in need of such treatment by administering a pharmaceutical composition 15 in accordance with the present invention as defined above.

In addition, in accordance with the present invention, a method is provided for preventing or treating diabetes, especially Type 2 diabetes, and 20 related diseases such as insulin resistance, hyperglycemia, hyperinsulinemia, elevated blood levels of fatty acids or glycerol, obesity, Syndrome X, diabetic complications, dysmetabolic syndrome, and related diseases, and sexual dysfunction, wherein a 25 therapeutically effective amount of a compound of structure I is administered to a patient in need of treatment.

In addition, in accordance with the present invention, a method is provided for preventing and 30 treating malignant lesions (such as ductal carcinoma in situ of the breast and lobular carcinoma in situ of the breast), premalignant lesions (such as fibroadenoma of the breast and prostatic intraepithelial neoplasia (PIN), gastrointestinal malignancies, liposarcomas and various 35 other epithelial tumors (including breast, prostate, colon, ovarian, gastric and lung), cancer-induced asthenia (fatigue), irritable bowel syndrome, Crohn's

disease, gastric ulceritis, and gallstones, and HIV infection, other infectious diseases, drug-induced lipodystrophy, and proliferative diseases such as psoriasis, wherein a therapeutically effective amount of 5 a compound of structure I is administered to a human patient in need of treatment.

In addition, in accordance with the present invention, a method is provided for improving coagulation homeostasis including reducing plasminogen activating 10 inhibitor (PAI)-1 activity, reducing fibrinogen, and/or reducing platelet aggregation, and/or improving endothelial function, wherein a therapeutically effective amount of a compound of structure I is administered to a patient in need of treatment.

15 In addition, in accordance with the present invention, a method is provided for treating cholesterol related diseases, diabetes and related diseases, cardiovascular diseases, cerebrovascular diseases as defined above and hereinafter and other diseases as set 20 out above, wherein a therapeutically effective amount of a combination of a compound of structure I and a hypolipidemic agent, and/or lipid modulating agent and/or antidiabetic agent and/or cardiovascular agent, cerebrovascular agent, and/or other type of therapeutic 25 agent, is administered to a patient in need of treatment.

In the above methods of the invention wherein a combination is administered, the compound of structure I will be employed in a weight ratio to the other therapeutic agent (depending upon its mode of operation) 30 within the range from about 0.01:1 to about 500:1, preferably from about 0.5:1 to about 100:1.

35 In accordance with the present invention, there is provided compounds useful in inhibiting the enzyme HMG-CoA reductase, which inhibitors are useful as hypocholesterolemic agents, dyslipidemic agents,

hypolipidemic agents, hypotriglyceridemic agents, anti-Alzheimer's disease agents, and antiosteoporosis agents as well as other uses as described herein.

The term "coronary events" as employed herein
5 refers to myocardial infarction, myocardial revascularization procedures, angina, cardiovascular death and acute coronary syndrome.

The term "cardiovascular diseases or events" as employed herein refers to atherosclerosis of the coronary
10 arteries, myocardial infarction, including primary MI and secondary MI, recurrent myocardial infarction, angina pectoris (including stable and unstable angina), congestive heart failure, and sudden cardiac death.

The term "cerebrovascular diseases or events" as
15 employed herein refers to cerebral infarction or stroke (caused by vessel blockage or hemorrhage), or transient ischemia attack (TIA), syncope, atherosclerosis of the intracranial and/or extracranial arteries, and the like.

The term "cholesterol-related diseases" as
20 employed herein refers to diseases involving elevated levels of LDL cholesterol, diseases involving regulation of LDL receptors, diseases involving reduced levels of HDL cholesterol, dyslipidemia, hyperlipidemia, elevated LDL Pattern B, elevated LDL Pattern A,
25 hypercholesterolemia, hypo α -lipoproteinemia (low HDL cholesterol syndrome), hyperlipoproteinemia, elevated Lp(a) levels, hypertriglyceridemia, other aberrations of apolipoprotein B metabolism, heterozygous familial, presumed familial combined and non-familial (non-FH)
30 forms of primary hypercholesterolemia (including Frederickson Types IIa and IIb), cholesterol ester storage disease, and cholesterol ester transfer protein disease, and related diseases.

The conditions, diseases, and maladies
35 collectively referenced to as "Syndrome X" or Dysmetabolic Syndrome (as detailed in Johanson, *J. Clin. Endocrinol. Metab.*, 1997, 82, 727-734, and other

publications) include hyperglycemia and/or prediabetic insulin resistance syndrome, and is characterized by an initial insulin resistant state generating hyperinsulinemia, dyslipidemia, and impaired glucose tolerance, which can progress to Type II diabetes, characterized by hyperglycemia, which can progress to diabetic complications.

The term "diabetes and related diseases" refers to Type II diabetes, Type I diabetes, impaired glucose tolerance, obesity, hyperglycemia, Syndrome X, dysmetabolic syndrome, diabetic complications and hyperinsulinemia.

The conditions, diseases and maladies collectively referred to as "diabetic complications" include retinopathy, neuropathy and nephropathy, and other known complications of diabetes.

The term "other type(s) of therapeutic agents" as employed herein refers to one or more antidiabetic agents (other than compounds of formula I), one or more anti-obesity agents, and/or one or more lipid-lowering agents, one or more lipid modulating agents (including anti-atherosclerosis agents), other types of anti-atherosclerosis agents, and/or one or more antiplatelet agents, one or more agents for treating hypertension, one or more anti-cancer drugs, one or more agents for treating arthritis, one or more anti-osteoporosis agents, one or more agents for treating immunomodulatory diseases.

The term "lipid-modulating" agent as employed herein refers to agents which lower LDL and/or raise HDL and/or lower triglycerides and/or lower total cholesterol and/or other known mechanisms for therapeutically treating lipid disorders.

The term "other types of anti-atherosclerosis agents" as employed herein refers to conventional anti-atherosclerosis agents including lipoxygenase inhibitors, ACAT inhibitors, antioxidants, PPAR agonists,

phospholipase inhibitors (including PLA-2 inhibitors), and/or other known anti-atherosclerosis agents.

The terms pharmaceutically acceptable "salt" and "salts" refer to basic salts formed with inorganic and 5 organic bases. Such salts include ammonium salts; alkali metal salts, such as lithium, sodium and potassium salts (which are preferred); alkaline earth metal salts, such as calcium and magnesium salts; salts with organic bases, such as amine like salts (e.g., dicyclohexylamine salt, 10 benzathine, N-methyl-D-glucamine, and hydrabamine salts); and salts with amino acids like arginine, lysine and the like; and zwitterions, the so-called "inner salts". Nontoxic, pharmaceutically acceptable salts are preferred, although other salts are also useful, e.g., in 15 isolating or purifying the product.


The term pharmaceutically acceptable "salt" and "salts" also includes acid addition salts. These are formed, for example, with strong inorganic acids, such as mineral acids, for example sulfuric acid, phosphoric acid 20 or a hydrohalic acid such as HCl or HBr, with strong organic carboxylic acids, such as alkanecarboxylic acids of 1 to 4 carbon atoms which are unsubstituted or substituted, for example, by halogen, for example acetic acid, such as saturated or unsaturated dicarboxylic 25 acids, for example oxalic, malonic, succinic, maleic, fumaric, phthalic or terephthalic acid, such as hydroxycarboxylic acids, for example ascorbic, glycolic, lactic, malic, tartaric or citric acid, such as amino acids, (for example aspartic or glutamic acid or lysine 30 or arginine), or benzoic acid, or with organic sulfonic acids, such as (C₁-C₄) alkyl or arylsulfonic acids which are unsubstituted or substituted, for example by halogen, for example methanesulfonic acid or p-toluenesulfonic acid.

35 The term "spirocyclic ring" as used in reference to (CH₂)_x and/or (CH₂)_y, refers to a 3 to 7 membered spirocyclic ring formed from one or more of the carbons

in $(\text{CH}_2)_x$ and/or one or more carbons in $(\text{CH}_2)_y$, together with additional carbons to make up a 3 to 7 membered ring.

Unless otherwise indicated, the term "lower alkyl", 5 "alkyl" or "alk" as employed herein alone or as part of another group includes both straight and branched chain hydrocarbons, containing 1 to 20 carbons, preferably 1 to 10 carbons, more preferably 1 to 8 carbons, in the normal chain, such as methyl, ethyl, propyl, isopropyl, butyl, 10 t-butyl, isobutyl, pentyl, hexyl, isoheptyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethyl-pentyl, nonyl, decyl, undecyl, dodecyl, the various branched chain isomers thereof, and the like as well as such groups including 1 to 4 substituents such as halo, for example 15 F, Br, Cl or I or CF_3 , alkyl, alkoxy, aryl, aryloxy, aryl(aryl) or diaryl, arylalkyl, arylalkyloxy, alkenyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkyloxy, amino, hydroxy, hydroxyalkyl, acyl, cycloheteroalkyl, heteroaryl, heteroaryloxy, heteroarylalkyl, 20 heteroarylalkoxy, aryloxyalkyl, alkylthio, arylalkylthio, aryloxyaryl, alkylamido, alkanoylamino, arylcarbonylamino, nitro, cyano, thiol, haloalkyl, trihaloalkyl and/or alkylthio.

Unless otherwise indicated, the term "cycloalkyl" 25 as employed herein alone or as part of another group includes saturated or partially unsaturated (containing 1 or 2 double bonds) cyclic hydrocarbon groups containing 1 to 3 rings, including monocyclic alkyl, bicyclic alkyl (or bicycloalkyl) and tricyclic alkyl, containing a total 30 of 3 to 20 carbons forming the ring, preferably 3 to 10 carbons, forming the ring and which may be fused to 1 or 2 aromatic rings as described for aryl, which includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl and cyclododecyl, 35 cyclohexenyl,



- any of which groups may be optionally substituted with 1 to 4 substituents such as halogen, alkyl, alkoxy, hydroxy, aryl, aryloxy, arylalkyl, cycloalkyl, alkylamido, alkanoylamino, oxo, acyl, arylcarbonylamino, heteroaryl, cycloheteroalkyl, amino, alkylamino, nitro, cyano, thiol and/or alkylthio and/or any of the substituents for alkyl.
- The term "cycloalkenyl" as employed herein alone or as part of another group refers to cyclic hydrocarbons containing 3 to 12 carbons, preferably 5 to 10 carbons and 1 or 2 double bonds. Exemplary cycloalkenyl groups include cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclohexadienyl, and cycloheptadienyl, which may be optionally substituted as defined for cycloalkyl.

The term "alkanoyl" as used herein alone or as part of another group refers to alkyl linked to a carbonyl group.

Unless otherwise indicated, the term "lower alkenyl" or "alkenyl" as used herein by itself or as part of another group refers to straight or branched chain radicals of 2 to 20 carbons, preferably 2 to 12 carbons, and more preferably 1 to 8 carbons in the normal chain, which include one to six double bonds in the normal chain, such as vinyl, 2-propenyl, 3-butenyl, 2-butenyl, 4-pentenyl, 3-pentenyl, 2-hexenyl, 3-hexenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 3-octenyl, 3-nonenyl, 4-decenyl, 3-undecenyl, 4-dodecenyl, 4,8,12-tetradecatrienyl, and the like, and which may be optionally substituted with 1

to 4 substituents, namely, halogen, haloalkyl, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl, amino, hydroxy, heteroaryl, cycloheteroalkyl, alkanoylamino, alkylamido, arylcarbonyl-amino, nitro, 5 cyano, thiol, alkylthio and/or any of the alkyl substituents set out herein.

Unless otherwise indicated, the term "lower alkynyl" or "alkynyl" as used herein by itself or as part of another group refers to straight or branched chain 10 radicals of 2 to 20 carbons, preferably 2 to 12 carbons and more preferably 2 to 8 carbons in the normal chain, which include one triple bond in the normal chain, such as 2-propynyl, 3-butynyl, 2-butynyl, 4-pentynyl, 3-pentynyl, 2-hexynyl, 3-hexynyl, 2-heptynyl, 3-heptynyl, 15 4-heptynyl, 3-octynyl, 3-nonynl, 4-decynyl, 3-undecynyl, 4-dodecynyl and the like, and which may be optionally substituted with 1 to 4 substituents, namely, halogen, haloalkyl, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl, amino, heteroaryl, 20 cycloheteroalkyl, hydroxy, alkanoylamino, alkylamido, arylcarbonylamino, nitro, cyano, thiol, and/or alkylthio, and/or any of the alkyl substituents set out herein.

The terms "arylalkenyl" and "arylalkynyl" as used alone or as part of another group refer to alkenyl and 25 alkynyl groups as described above having an aryl substituent.

Where alkyl groups as defined above have single bonds for attachment to other groups at two different carbon atoms, they are termed "alkylene" groups and may 30 optionally be substituted with 1 or 2 substituents as defined above for "alkyl", such as, for example alkyl, halo, hydroxy, alkoxy and/or cycloalkyl.









Where alkenyl groups as defined above and alkynyl groups as defined above, respectively, have single bonds 35 for attachment at two different carbon atoms, they are

termed "alkenylene groups" and "alkynylene groups", respectively, and may optionally be substituted with 1 or 2 substituents as defined above for "alkenyl" and "alkynyl".

5 $(\text{CH}_2)_x$ or $(\text{CH}_2)_y$ includes alkylene groups as defined herein, which may optionally include 1, 2, or 3 substituents which include alkyl, alkenyl, halogen, aryl, hydroxy, alkoxy, or $\text{C}_3\text{-}\text{C}_6$ cycloalkyl.

Examples of $(\text{CH}_2)_x$ or $(\text{CH}_2)_y$, alkylene groups

10 include $-\text{CH}_2-$, $-\text{CH}_2\text{CH}_2-$,




25

The term "halogen" or "halo" as used herein alone or as part of another group refers to chlorine, bromine,

fluorine, and iodine as well as CF_3 , with chlorine or fluorine being preferred.

The term "metal ion" refers to alkali metal ions such as sodium, potassium or lithium and alkaline earth metal ions such as magnesium and calcium, as well as zinc and aluminum.

Unless otherwise indicated, the term "aryl" as employed herein alone or as part of another group refers to monocyclic and bicyclic aromatic groups containing 6 to 10 carbons in the ring portion (such as phenyl or naphthyl including 1-naphthyl and 2-naphthyl) and may optionally include one to three additional rings fused to a carbocyclic ring or a heterocyclic ring (such as aryl, cycloalkyl, heteroaryl or cycloheteroalkyl rings for example



and may be optionally substituted through available carbon atoms with 1, 2, or 3 groups selected from 20 hydrogen, halo, haloalkyl, alkyl, haloalkyl, alkoxy, halophenyl, benzoxyloxy, haloalkoxy, alkenyl, trifluoromethyl, trifluoromethoxy, alkynyl, cycloalkyl-alkyl, cycloheteroalkyl, cycloheteroalkylalkyl, aryl, heteroaryl, arylalkyl, aryloxy, aryloxyalkyl, arylalkoxy, 25 arylthio, arylazo, heteroarylalkyl, heteroarylalkenyl, heteroarylheteroaryl, heteroaryloxy, hydroxy, nitro, cyano, amino, substituted amino wherein the amino includes 1 or 2 substituents (which are alkyl, alkanoyl, aryl or any of the other aryl compounds mentioned in the

definitions), thiol, alkylthio, arylthio, heteroarylthio, arylthioalkyl, alkoxyarylthio, alkylcarbonyl, arylcarbonyl, alkyl-aminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aminocarbonyl, alkylcarbonyloxy,
5 arylcarbonyloxy, alkylcarbonylamino, arylcarbonylamino, arylsulfinyl, arylsulfinylalkyl, arylsulfonylamino or arylsulfon-aminocarbonyl and/or any of the alkyl substituents set out herein.

Unless otherwise indicated, the term "lower
10 alkoxy", "alkoxy", "aryloxy" or "aralkoxy" as employed herein alone or as part of another group includes any of the above alkyl, aralkyl or aryl groups linked to an oxygen atom.


Unless otherwise indicated, the term "substituted
15 amino" as employed herein alone or as part of another group refers to amino substituted with one or two substituents, which may be the same or different, such as alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, cycloalkyl,
20 cycloalkylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl or thioalkyl. These substituents may be further substituted with a carboxylic acid and/or any of the substituents for alkyl as set out above. In addition, the amino substituents may be taken together with the nitrogen atom
25 to which they are attached to form 1-pyrrolidinyl, 1-piperidinyl, 1-azepinyl, 4-morpholinyl, 4-thiomorpholinyl, 1-piperazinyl, 4-alkyl-1-piperazinyl, 4-arylalkyl-1-piperazinyl, 4-diarylalkyl-1-piperazinyl, 1-pyrrolidinyl, 1-piperidinyl, or 1-azepinyl, optionally
30 substituted with alkyl, alkoxy, alkylthio, halo, trifluoromethyl or hydroxy.

Unless otherwise indicated, the term "lower alkylthio", alkylthio", "arylthio" or "aralkylthio" as employed herein alone or as part of another group
35 includes any of the above alkyl, aralkyl or aryl groups linked to a sulfur atom.

Unless otherwise indicated, the term "lower alkylamino", "alkylamino", "aryl amino", or "arylalkylamino" as employed herein alone or as part of another group includes any of the above alkyl, aryl or 5 arylalkyl groups linked to a nitrogen atom.

Unless otherwise indicated, the term "acyl" as employed herein by itself or part of another group, as defined herein, refers to an organic radical linked to a carbonyl ($\text{C}=\text{O}$) group; examples of acyl groups include 10 any of the R¹ groups attached to a carbonyl, such as alkanoyl, alkenoyl, aroyl, aralkanoyl, heteroaroyl, cycloalkanoyl, cycloheteroalkanoyl and the like.

Unless otherwise indicated, the term "cycloheteroalkyl" as used herein alone or as part of 15 another group refers to a 5-, 6- or 7-membered saturated or partially unsaturated ring which includes 1 to 2 hetero atoms such as nitrogen, oxygen and/or sulfur, linked through a carbon atom or a heteroatom, where possible, optionally via the linker (CH₂)_r (where r is 1, 20 2 or 3), such as




25 and the like. The above groups may include 1 to 4 substituents such as alkyl, halo, oxo and/or any of of

the alkyl substituents set out herein. In addition, any of the cycloheteroalkyl rings can be fused to a cycloalkyl, aryl, heteroaryl or cycloheteroalkyl ring.

- Unless otherwise indicated, the term "heteroaryl" 5 as used herein alone or as part of another group refers to a 5- or 6-membered aromatic ring which includes 1, 2, 3 or 4 hetero atoms such as nitrogen, oxygen or sulfur, and such rings fused to an aryl, cycloalkyl, heteroaryl or cycloheteroalkyl ring (e.g. 10 benzothiophenyl, indolyl), and includes possible N-oxides. The heteroaryl group may optionally include 1 to 4 substituents such as any of the substituents set out above for alkyl. Examples of heteroaryl groups include the following:

15



and the like.

- The term "cycloheteroalkylalkyl" as used herein alone or as part of another group refers to 25 cycloheteroalkyl groups as defined above linked through a C atom or heteroatom to a $(CH_2)_r$ chain.

The term "heteroarylalkyl" or "heteroarylalkenyl" as used herein alone or as part of another group refers

to a heteroaryl group as defined above linked through a C atom or heteroatom to a -(CH₂)_r- chain, alkylene or alkenylene as defined above.


The term "polyhaloalkyl" as used herein refers to 5 an "alkyl" group as defined above which includes from 2 to 9, preferably from 2 to 5, halo substituents, such as F or Cl, preferably F, such as CF₃CH₂, CF₃ or CF₃CF₂CH₂.

The term "polyhaloalkoxy" as used herein refers to 10 an "alkoxy" or "alkyloxy" group as defined above which includes from 2 to 9, preferably from 2 to 5, halo substituents, such as F or Cl, preferably F, such as CF₃CH₂O, CF₃O or CF₃CF₂CH₂O.

All stereoisomers of the compounds of the instant invention are contemplated, either in admixture or in 15 pure or substantially pure form. The compounds of the present invention can have asymmetric centers at any of the carbon atoms including any one or the R substituents. Consequently, compounds of formula I can exist in enantiomeric or diastereomeric forms or in mixtures 20 thereof. The processes for preparation can utilize racemates, enantiomers or diastereomers as starting materials. When diastereomeric or enantiomeric products are prepared, they can be separated by conventional methods for example, chromatographic or fractional 25 crystallization.


The term "prodrug esters" as employed herein includes esters and carbonates formed by reacting one or more hydroxyls of compounds of formula I with alkyl, alkoxy, or aryl substituted acylating agents employing 30 procedures known to those skilled in the art to generate acetates, pivalates, methylcarbonates, benzoates and the like. In addition, prodrug esters which are known in the art for carboxylic and phosphorus acid esters such as methyl, ethyl, benzyl and the like.

Examples of such prodrug esters include



Other examples of suitable prodrug esters include

5



wherein R^a can be H, alkyl (such as methyl or *t*-butyl), arylalkyl (such as benzyl) or aryl (such as phenyl); R^d is H, alkyl, halogen or alkoxy, R^e is alkyl, aryl, arylalkyl or alkoxy, and n_1 is 0, 1 or 2.


Compounds of the invention may be prepared by the following method.


Referring to Reaction Scheme 1, Knovenagel condensation of readily available beta-keto ester 1, where R is lower alkyl, with aldehyde 2 under standard conditions (e.g. HOAc, piperidine, toluene, reflux) affords the corresponding adduct 3. Base induced 1,4-addition of ketone 4 (e.g. LiN(TMS)₂, or NaHDMS in THF or EtONa in EtOH) provides the adduct 5, usually as a mixture of diastereomers.

Conversion of the 1,5-diketone 5 to the pyridyl ester 6 may be effected by treatment with an ammonia source (such as NH₄OAc) in the presence of an oxidant (such as Cu(OAc)₂ or oxygen) in a suitable solvent (such as refluxing HOAc), or by reaction of 5 with hydroxylamine hydrochloride in HOAc with heat. The ester functionality of 6 can be reduced by standard methods (LiAlH₄, DIBAL, LiBH₄) to give alcohol 7 which can subsequently be converted to the corresponding halide 8

(e.g. PBr_3 in CH_2Cl_2 , $\text{CBr}_4/\text{PPh}_3$ in CH_3CN , or POCl_3). Conversion of halide 8 to the phosphorus compound 9 where W is Ph or alkyl is effected by treatment of 8 with W_2POEt in toluene. Conversion of halide 8 to compound 9 where W is OR (R is lower alkyl) may be effected by the reaction of 8 with $\text{HOP(OR)}_2/\text{base/THF}$ or by Arbuzov reaction with P(OR)_3 . Wittig reaction between 9 and aldehyde 10 (aldehyde 10 has been previously described in US patent 5,686,433) may be effected under standard conditions with base ($n\text{-BuLi}$, $\text{LiN}(\text{TMS})_2$, LDA) in an appropriate solvent (THF, Et_2O , toluene, DMPU) to afford the adduct 11. Treatment of 11 under acidic conditions (e.g. TFA, HCl) effects the conversion of 11 to lactone Ia. Saponification of Ia to Ib (where R_3 is alkali metal, or alkaline earth metal) can be effected by treatment of Ia with aqueous base or subsequently acidified to give Ib where R_3 is H. Additionally, Ia can be treated with an alcohol of the type R_3OH under basic conditions to form the corresponding esters of Ib.


As seen in Reaction Scheme 2, the saturated derivatives of compound I (where \equiv is $\text{CH}_2\text{-CH}_2$) are obtained by catalytic (Pd/C , Pt/C , Pd(OH)_2) hydrogenation of 11, Ia, or Ib to afford 12, Ic, or Id, respectively. Compound 12 may be converted to Ic and Id following the earlier described methods for the conversion of compound 11 to Ia and Ib.

Scheme 1

Scheme 2


The synthesis of compounds I wherein $\text{--}\equiv\text{--}$ is CH=CH and n is 1, is described in Scheme 3. Bis-silylation of compound Ib¹ with a bulky silylchloride (e.g., ClSi(t-butyl)Ph₂, ClSi(t-butyl)Me₂, ClSiPh₃) in the presence of a suitable base (e.g., TEA, imidazole, pyridine) and solvent (e.g., CH₂Cl₂, THF) provides compound Ib². Treatment of Ib² with oxidants such as m-CPBA or CF₃CO₃H in an appropriate solvent such as CH₂Cl₂ or HOAc affords N-oxide Ib³. Desilylation of Ib³ (TBAF/HOAc/THF or HF/CH₃CN) gives Ib⁴ which may be saponified to Ib⁵ using aqueous solutions of a metal hydroxide in an appropriate solvent (e.g., MeOH, dioxane).

SCHEME 3




Additionally, compound Id¹ may be oxidized and saponified, as described above, to provide compounds I wherein ~~—CH₂CH₂—~~ is CH₂CH₂ and n is 1 (e.g., compounds Id² and ID³) as shown in Scheme 4.

5

SCHEME 4

Referring to Scheme 5, the arginine salt of the compounds of formula I of the invention may be prepared by treating alkali metal salt (preferably sodium) Ib with acid (TFA, HCl) to form the acid Ib⁶ which is treated 5 with arginine in the presence of suitable solvents such as ethyl alcohol and H₂O, ethyl acetate, acetonitrile and the like, to form arginine salt Ib⁷.

Scheme 5




10


Scheme 6 depicts a preferred method for preparing the HMG CoA reductase inhibitor of formula I of the invention using the Julia-Kocienski olefination reaction employing 4-pyridyl carboxylaldehyde (18) and chiral sulfone (16). The desired *trans* intermediate (19) is isolated in high yield and optical purity which is converted to the final product of the invention. As will be seen, the chiral sulfone (16), a key intermediate in the Julia-Kocienski step, is prepared in three steps starting from the commercially available Kaneka alcohol (12) via triflate (13) and sulfide intermediate (15).

Referring to Scheme 6, treatment of commercially available chiral alcohol (12) with triflic anhydride and triethylamine in dichloromethane at low temperature (for example 0 to -30°C) affords triflate (13). Other 5 pyridine or amine bases may be employed. Triflate (13) (without being isolated) is carried onto the next step without further purification. A methylene chloride solution of triflate (13) is treated with 1-phenyl-1H-tetrazole-5-thiol (14) to provide the chiral sulfide (15) 10 which is oxidized with hydrogen peroxide in the presence of catalytic ammonium heptamolybdate tetrahydrate to give crystalline sulfone (16). Other oxidant, such as m-chloro-p-benzoic acid (mCPBA) may be employed.

Addition of LiHMDS or NaHMDS to a mixture of 15 sulfone (16) and pyridine carboxylaldehyde (18) in THF at low temperature (-78 to -35°C) provides *trans* olefin (19) in high diastereoselectivity (>99%).


The pyridine aldehyde (18) is obtained as a crystalline solid from the corresponding ester (17). 20 Reduction of ester (17) with Red-Al followed by oxidation with Tempo (2,2,6,6-tetramethyl-1-piperidinyloxy) gives aldehyde (18) in high yield. The final compound Ib⁹ of the invention is prepared in a one pot procedure starting from (19) without isolating any intermediates. Removal 25 of acetonide under acidic condition provides diol (20) which upon further treatment with sodium hydroxide gives the sodium salt of the acid (21). Subsequent treatment of 21 with acid followed by the addition of arginine produces crystalline arginine salt of the invention Ib⁹.

Scheme 6






In addition, in accordance with the present invention, intermediates 6, 7, 8, 9, 11 and 12 are novel 5 compounds and form part of the present invention. These compounds have the general structure

II




wherein x, y, R₁, R₂, R₄ are as defined above, Q is

10



Thus, the intermediates of the invention can have the following structures:



Compounds containing dihydroxy acid HMG-CoA binding domain side chains may be prepared in homochiral form, which is preferred, or may be prepared as racemic mixtures ($3S^*$, $5R^*$) and may later be resolved to obtain the $3S$, $5R$ isomer.

The compounds of the invention are inhibitors of 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase and thus are useful in inhibiting cholesterol biosynthesis and/or in lowering triglycerides, in a manner similar to atorvastatin, pravastatin, simvastatin, lovastatin, cerivastatin, visastatin (or rosuvastatin) (Astra Zeneca ZD4522), fluvastatin, itavastatin (or pitavastatin) and the like.

A further aspect of the present invention is a pharmaceutical composition containing at least one of the compounds of formula I of the present invention in association with a pharmaceutical vehicle or diluent.

The pharmaceutical composition can be formulated employing conventional solid or liquid vehicles of diluents and pharmaceutical additives of a type appropriate to the mode of desired administration. The 5 compounds can be administered by an oral route, for example, in the form of tablets, capsules, granules or powders, or they can be administered by a parenteral route in the form of injectable preparations. Such dosage forms contain from 0.1 to 1500 mg of active 10 compound per dosage, for use in the treatment. The dose to be administered depends on the unitary dose, the symptoms, and the age and the body weight of the patient.

The compounds of the present invention can be administered in a similar manner as known compounds 15 suggested for use in inhibiting cholesterol biosynthesis, such as pravastatin, lovastatin, simvastatin, visastatin (or rosuvastatin), atorvastatin, cerivastatin, fluvastatin, itavastatin (or pitavastatin), and the like, in mammalian species such as humans, dogs, cats and the 20 like. Thus, the compounds of the invention may be administered in an amount from about 0.1 to 500 mg in a single dose or in the form of individual doses from 1 to 4 times per day, preferably 0.2 to 100 mg daily or in sustained release form.

25 The HMG CoA reductase inhibitors of formula I may be employed in combination with all therapeutic agents which are useful in combination with HMG CoA reductase inhibitors.

Thus, where desired, the compounds of structure I 30 may be used in combination with one or more hypolipidemic agents or lipid-lowering agents, or lipid agents, or lipid modulating agents, and/or one or more other types of therapeutic agents including antidiabetic agents, anti-obesity agents, antihypertensive agents, platelet 35 aggregation inhibitors, anti-Alzheimer's agents, anti-dementia agents, anti-osteoporosis agents, and/or hormone replacement therapeutic agents, and/or other therapeutic

agents, and/or other cardiovascular agents (including anti-anginal agents, anti-arrhythmic agents, anti-atherosclerosis agents, anti-inflammatory agents, anti-platelet agents, anti-heart failure agents), anti-cancer agents, anti-infective agents, hormone replacement agents, growth hormone secretagogues, selective androgen receptor modulators, and/or other therapeutic agents which may be administered orally in the same dosage form or in a separate oral dosage form, or by injection.


10 The hypolipidemic agent or lipid-lowering agent or other lipid agent or lipid modulating agent which may be optionally employed in combination with the compounds of formula I of the invention may include 1,2,3 or more MTP inhibitors, HMG CoA reductase inhibitors, squalene synthetase inhibitors, PPAR α agonists, PPAR dual α/γ agonists, PPAR δ agonists, fibric acid derivatives, ACAT inhibitors, lipoxygenase inhibitors, cholesterol absorption inhibitors, ileal Na⁺/bile acid cotransporter inhibitors, upregulators of LDL receptor activity, cholesteryl ester transfer protein inhibitors, bile acid sequestrants, and/or nicotinic acid and derivatives thereof.

 MTP inhibitors employed herein include MTP inhibitors disclosed in U.S. Patent No. 5,595,872, U.S. Patent No. 5,739,135, U.S. Patent No. 5,712,279, U.S. Patent No. 5,760,246, U.S. Patent No. 5,827,875, U.S. Patent No. 5,885,983 and U.S. Application Serial No. 09/175,180 filed October 20, 1998, now U.S. Patent No. 5,962,440. Preferred are each of the preferred MTP inhibitors disclosed in each of the above patents and applications.

 All of the above U.S. Patents and applications are incorporated herein by reference.

 Most preferred MTP inhibitors to be employed in accordance with the present invention include preferred MTP inhibitors as set out in U.S. Patent Nos. 5,739,135 and 5,712,279, and U.S. Patent No. 5,760,246.

The most preferred MTP inhibitor is 9-[4-[4-[[2-(2,2,2-Trifluoroethoxy)benzoyl]amino]-1-piperidinyl]butyl]-N-(2,2,2-trifluoroethyl)-9H-fluorene-9-carboxamide



5

The hypolipidemic agent may be an HMG CoA reductase inhibitor which includes, but is not limited to, mevastatin and related compounds as disclosed in U.S. Patent No. 3,983,140, lovastatin (mevinolin) and related compounds as disclosed in U.S. Patent No. 4,231,938, pravastatin and related compounds such as disclosed in U.S. Patent No. 4,346,227, simvastatin and related compounds as disclosed in U.S. Patent Nos. 4,448,784 and 4,450,171. Other HMG CoA reductase inhibitors which may be employed herein include, but are not limited to, fluvastatin, disclosed in U.S. Patent No. 5,354,772, cerivastatin disclosed in U.S. Patent Nos. 5,006,530 and 5,177,080, atorvastatin disclosed in U.S. Patent Nos. 4,681,893, 5,273,995, 5,385,929 and 5,686,104, pitavastatin (Nissan/Sankyo's nisvastatin (NK-104) or itavastatin), disclosed in U.S. Patent No. 5,011,930, Shionogi-Astra/Zeneca rosuvastatin (visastatin (ZD-4522)) disclosed in U.S. Patent No. 5,260,440, and related statin compounds disclosed in U.S. Patent No. 5,753,675, pyrazole analogs of mevalonolactone derivatives as disclosed in U.S. Patent No. 4,613,610, indene analogs of mevalonolactone derivatives as disclosed in PCT application WO 86/03488, 6-[2-(substituted-pyrrol-1-yl)-alkyl]pyran-2-ones and derivatives thereof as disclosed in U.S. Patent No. 4,647,576, Searle's SC-45355 (a 3-

substituted pentanedioic acid derivative) dichloroacetate, imidazole analogs of mevalonolactone as disclosed in PCT application WO 86/07054, 3-carboxy-2-hydroxy-propane-phosphonic acid derivatives as disclosed
5 in French Patent No. 2,596,393, 2,3-disubstituted pyrrole, furan and thiophene derivatives as disclosed in European Patent Application No. 0221025, naphthyl analogs of mevalonolactone as disclosed in U.S. Patent No. 4,686,237, octahydronaphthalenes such as disclosed in
10 U.S. Patent No. 4,499,289, keto analogs of mevinolin (lovastatin) as disclosed in European Patent Application No. 0,142,146 A2, and quinoline and pyridine derivatives disclosed in U.S. Patent No. 5,506,219 and 5,691,322.

In addition, phosphinic acid compounds useful in
15 inhibiting HMG CoA reductase suitable for use herein are disclosed in GB 2205837.

The squalene synthetase inhibitors suitable for use herein include, but are not limited to, α -phosphono-sulfonates disclosed in U.S. Patent No. 5,712,396, those
20 disclosed by Biller et al, J. Med. Chem., 1988, Vol. 31, No. 10, pp 1869-1871, including isoprenoid (phosphinyl-methyl)phosphonates as well as other known squalene synthetase inhibitors, for example, as disclosed in U.S. Patent No. 4,871,721 and 4,924,024 and in Biller, S.A.,
25 Neuenschwander, K., Ponpipom, M.M., and Poulter, C.D., Current Pharmaceutical Design, 2, 1-40 (1996).

In addition, other squalene synthetase inhibitors suitable for use herein include the terpenoid pyrophosphates disclosed by P. Ortiz de Montellano et al, J. Med. Chem., 1977, 20, 243-249, the farnesyl diphosphate analog A and presqualene pyrophosphate (PSQ-PP) analogs as disclosed by Corey and Volante, J. Am. Chem. Soc., 1976, 98, 1291-1293, phosphinylphosphonates reported by McClard, R.W. et al, J.A.C.S., 1987, 109, 35 5544 and cyclopropanes reported by Capón, T.L., PhD dissertation, June, 1987, Dept. Med. Chem. U of Utah,

Abstract, Table of Contents, pp 16, 17, 40-43, 48-51,
Summary.

Other hypolipidemic agents suitable for use herein include, but are not limited to, fibric acid derivatives, 5 such as fenofibrate, gemfibrozil, clofibrate, bezafibrate, ciprofibrate, clinofibrate and the like, probucol, and related compounds as disclosed in U.S. Patent No. 3,674,836, probucol and gemfibrozil being preferred, bile acid sequestrants such as cholestyramine, 10 colestipol and DEAE-Sephadex (Secholex®, Policexide®) and cholestagel (Sankyo/Geltex), as well as lipostabil (Rhone-Poulenc), Eisai E-5050 (an N-substituted ethanolamine derivative), imanixil (HOE-402), tetrahydrolipstatin (THL), istigmastanylphosphorylcholine (SPC, Roche), aminocyclodextrin (Tanabe Seiyoku), Ajinomoto AJ-814 (azulene derivative), melinamide (Sumitomo), Sandoz 58-035, American Cyanamid CL-277,082 and CL-283,546 (disubstituted urea derivatives), nicotinic acid (niacin), acipimox, acifran, 20 neomycin, p-aminosalicylic acid, aspirin, poly(diallylmethylamine) derivatives such as disclosed in U.S. Patent No. 4,759,923, quaternary amine poly(diallyldimethylammonium chloride) and ionenes such as disclosed in U.S. Patent No. 4,027,009, and other 25 known serum cholesterol lowering agents.

The other hypolipidemic agent may be an ACAT inhibitor (which also has anti-atherosclerosis activity) such as disclosed in, Drugs of the Future 24, 9-15 (1999), (Avasimibe); "The ACAT inhibitor, Cl-1011 is effective in the prevention and regression of aortic fatty streak area in hamsters", Nicolosi et al, Atherosclerosis (Shannon, Irel). (1998), 137(1), 77-85; "The pharmacological profile of FCE 27677: a novel ACAT inhibitor with potent hypolipidemic activity mediated by 30 selective suppression of the hepatic secretion of ApoB100-containing lipoprotein", Ghiselli, Giancarlo, Cardiovasc. Drug Rev. (1998), 16(1), 16-30; "RP 73163: a 35

bioavailable alkylsulfinyl-diphenylimidazole ACAT inhibitor", Smith, C., et al, Bioorg. Med. Chem. Lett. (1996), 6(1), 47-50; "ACAT inhibitors: physiologic mechanisms for hypolipidemic and anti-atherosclerotic activities in experimental animals", Krause et al, Editor(s): Ruffolo, Robert R., Jr.; Hollinger, Mannfred A., Inflammation: Mediators Pathways (1995), 173-98, Publisher: CRC, Boca Raton, Fla.; "ACAT inhibitors: potential anti-atherosclerotic agents", Sliskovic et al, Curr. Med. Chem. (1994), 1(3), 204-25; "Inhibitors of acyl-CoA:cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. 6. The first water-soluble ACAT inhibitor with lipid-regulating activity. Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N'-(1-phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity", Stout et al, Chemtracts: Org. Chem. (1995), 8(6), 359-62, or TS-962 (Taisho Pharmaceutical Co. Ltd), as well as F-1394, CS-505, F-12511, HL-004, K-10085 and YIC-C8-434.

The hypolipidemic agent may be an upregulator of LDL receptor activity such as MD-700 (Taisho Pharmaceutical Co. Ltd) and LY295427 (Eli Lilly).

The hypolipidemic agent may be a cholesterol absorption inhibitor preferably Schering-Plough's SCH48461 (ezetimibe) as well as those disclosed in Atherosclerosis 115, 45-63 (1995) and J. Med. Chem. 41, 973 (1998).

The other lipid agent or lipid-modulating agent may be a cholesteryl transfer protein inhibitor (CETP) such as Pfizer's CP-529,414 as well as those disclosed in WO/0038722 and in EP 818448 (Bayer) and EP 992496, and Pharmacia's SC-744 and SC-795, as well as CETi-1 and JTT-705.

The hypolipidemic agent may be an ileal Na⁺/bile acid cotransporter inhibitor such as disclosed in Drugs of the Future, 24, 425-430 (1999).

- The ATP citrate lyase inhibitor which may be employed in the combination of the invention may include, for example, those disclosed in U.S. Patent No. 5,447,954.
- 5 The other lipid agent also includes a phytoestrogen compound such as disclosed in WO 00/30665 including isolated soy bean protein, soy protein concentrate or soy flour as well as an isoflavone such as genistein, daidzein, glycitein or equol, or phytosterols, 10 phytostanol or tocotrienol as disclosed in WO 2000/015201;
- a beta-lactam cholesterol absorption inhibitor such as disclosed in EP 675714;
- an HDL upregulator such as an LXR agonist, a PPAR 15 α-agonist and/or an FXR agonist;
- an α-glucosidase inhibitor, an aldose reductase inhibitor and/or an LDL catabolism promoter such as disclosed in EP 1022272;
- a sodium-proton exchange inhibitor such as 20 disclosed in DE 19622222;
- an LDL-receptor inducer or a steroidal glycoside such as disclosed in U.S. Patent No. 5,698,527 and GB 2304106;
- an anti-oxidant such as beta-carotene, ascorbic 25 acid, α-tocopherol or retinol as disclosed in WO 94/15592 as well as Vitamin C and an antihomocysteine agent such as folic acid, a folate, Vitamin B6, Vitamin B12 and Vitamin E;
- isoniazid as disclosed in WO 97/35576;
- 30 a cholesterol absorption inhibitor, an HMG-CoA synthase inhibitor, or a lanosterol demethylase inhibitor as disclosed in WO 97/48701;
- a PPAR δ agonist for treating dyslipidemia;
- or a sterol regulating element binding protein-I 35 (SREBP-1) as disclosed in WO 2000/050574, for example, a sphingolipid, such as ceramide, or neutral sphingomyelenase (N-SMase) or fragment thereof.

Preferred hypolipidemic agents are pravastatin, lovastatin, simvastatin, atorvastatin, fluvastatin, cerivastatin, pitavastatin and rosuvastatin, as well as niacin and/or cholestagel.

5 The above-mentioned U.S. patents are incorporated herein by reference. The amounts and dosages employed will be as indicated in the Physician's Desk Reference and/or in the patents set out above or as otherwise known in the art.

10 The compounds of formula I of the invention will be employed in a weight ratio to the hypolipidemic agent (where present), within the range from about 500:1 to about 1:500, preferably from about 100:1 to about 1:100.

15 The dose administered must be carefully adjusted according to age, weight and condition of the patient, as well as the route of administration, dosage form and regimen and the desired result.

20 The dosages and formulations for the hypolipidemic agent or other lipid agent or lipid modulating agent will be as disclosed in the various patents and applications discussed above.

25 The dosages and formulations for the other hypolipidemic agent or other lipid agent or lipid modulating agent to be employed, where applicable, will be as set out in the latest edition of the Physicians' Desk Reference.

30 For oral administration, a satisfactory result may be obtained employing the MTP inhibitor in an amount within the range of from about 0.01 mg to about 500 mg and preferably from about 0.1 mg to about 100 mg, one to four times daily.

35 A preferred oral dosage form, such as tablets or capsules, will contain the MTP inhibitor in an amount of from about 1 to about 500 mg, preferably from about 2 to about 400 mg, and more preferably from about 5 to about 250 mg, one to four times daily.

For oral administration, a satisfactory result may be obtained employing an HMG CoA reductase inhibitor, for example, pravastatin, lovastatin, simvastatin, atorvastatin, fluvastatin or cerivastatin in dosages 5 employed as indicated in the Physician's Desk Reference, such as in an amount within the range of from about 1 to 2000 mg, and preferably from about 4 to about 200 mg.

The squalene synthetase inhibitor may be employed in dosages in an amount within the range of from about 10 10 mg to about 2000 mg and preferably from about 25 mg to about 200 mg.

A preferred oral dosage form, such as tablets or capsules, will contain the HMG CoA reductase inhibitor in an amount from about 0.1 to about 100 mg, preferably from 15 about 0.5 to about 80 mg, and more preferably from about 1 to about 40 mg.

A preferred oral dosage form, such as tablets or capsules will contain the squalene synthetase inhibitor in an amount of from about 10 to about 500 mg, preferably 20 from about 25 to about 200 mg.

The anti-atherosclerotic agent includes a lipoxygenase inhibitor including a 15-lipoxygenase (15-LO) inhibitor such as benzimidazole derivatives as disclosed in WO 97/12615, 15-LO inhibitors as disclosed 25 in WO 97/12613, isothiazolones as disclosed in WO 96/38144, and 15-LO inhibitors as disclosed by Sendobry et al "Attenuation of diet-induced atherosclerosis in rabbits with a highly selective 15-lipoxygenase inhibitor lacking significant antioxidant properties," Brit. J. Pharmacology (1997) 120, 1199-1206, and Cornicelli et al, "15-Lipoxygenase and its Inhibition: A Novel Therapeutic Target for Vascular 30 Disease", Current Pharmaceutical Design, 1999, 5, 11-20.

The compounds of formula I and the hypolipidemic 35 agent may be employed together in the same oral dosage form or in separate oral dosage forms taken at the same time.

The compositions described above may be administered in the dosage forms as described above in single or divided doses of one to four times daily. It may be advisable to start a patient on a low dose 5 combination and work up gradually to a high dose combination.

The antidiabetic agent which may be optionally employed in combination with the HMG-CoA reductase inhibitor of formula I may be 1,2,3 or more antidiabetic 10 agents or antihyperglycemic agents including insulin secretagogues or insulin sensitizers, which may include biguanides, sulfonyl ureas, glucosidase inhibitors, aldose reductase inhibitors, PPAR γ agonists such as thiazolidinediones, PPAR α agonists (such as fibrin acid 15 derivatives), PPAR δ antagonists or agonists, aP2 inhibitors, PPAR α/γ dual agonists, dipeptidyl peptidase IV (DP4) inhibitors, SGLT2 inhibitors, glycogen phosphorylase inhibitors, and/or meglitinides, as well as insulin, and/or glucagon-like peptide-1 (GLP-1), and/or a 20 PTP-1B inhibitor (protein tyrosine phosphatase-1B inhibitor).

The antidiabetic agent may be an oral antihyperglycemic agent preferably a biguanide such as metformin or phenformin or salts thereof, preferably 25 metformin HCl.

Where the antidiabetic agent is a biguanide, the compounds of structure I will be employed in a weight ratio to biguanide within the range from about 0.001:1 to about 10:1, preferably from about 0.01:1 to about 5:1.

30 The antidiabetic agent may also preferably be a sulfonyl urea such as glyburide (also known as glibenclamide), glimepiride (disclosed in U.S. Patent No. 4,379,785), glipizide, gliclazide or chlorpropamide, other known sulfonylureas or other antihyperglycemic 35 agents which act on the ATP-dependent channel of the β -cells, with glyburide and glipizide being preferred,

which may be administered in the same or in separate oral dosage forms.

The compounds of structure I will be employed in a weight ratio to the sulfonyl urea in the range from about 5 0.01:1 to about 100:1, preferably from about 0.02:1 to about 5:1.

The oral antidiabetic agent may also be a glucosidase inhibitor such as acarbose (disclosed in U.S. Patent No. 4,904,769) or miglitol (disclosed in U.S. 10 Patent No. 4,639,436), which may be administered in the same or in a separate oral dosage forms.

The compounds of structure I will be employed in a weight ratio to the glucosidase inhibitor within the range from about 0.01:1 to about 100:1, preferably from 15 about 0.05:1 to about 10:1.

The compounds of structure I may be employed in combination with a PPAR γ agonist such as a thiazolidinedione oral anti-diabetic agent or other insulin sensitizers (which has an insulin sensitivity 20 effect in NIDDM patients) such as troglitazone (Warner-Lambert's Rezulin[®], disclosed in U.S. Patent No. 4,572,912), rosiglitazone (SKB), pioglitazone (Takeda), Mitsubishi's MCC-555 (disclosed in U.S. Patent No. 5,594,016), Glaxo-Welcome's GL-262570, englitazone (CP-25 68722, Pfizer) or darglitazone (CP-86325, Pfizer, isaglitazone (MIT/J&J), JTT-501 (JPNT/P&U), L-895645 (Merck), R-119702 (Sankyo/WL), NN-2344 (Dr. Reddy/NN), or YM-440 (Yamanouchi), preferably rosiglitazone and pioglitazone.

30 The compounds of structure I will be employed in a weight ratio to the thiazolidinedione in an amount within the range from about 0.01:1 to about 100:1, preferably from about 0.05:1 to about 10:1.

The sulfonyl urea and PPAR γ agonists in amounts of 35 less than about 150 mg oral antidiabetic agent may be incorporated in a single tablet with the compounds of structure I.

The compounds of structure I may also be employed in combination with a antihyperglycemic agent such as insulin or with glucagon-like peptide-1 (GLP-1) or mimetic such as GLP-1(1-36) amide, GLP-1(7-36) amide, GLP-1(7-37) (as disclosed in U.S. Patent No. 5,614,492 to Habener, the disclosure of which is incorporated herein by reference), as well as AC2993 (Amylen) and LY-315902 (Lilly), which may be administered via injection, 10 intranasal, inhalation or by transdermal or buccal devices.

Where present, metformin, the sulfonyl ureas, such as glyburide, glimepiride, glipizide, chlorpropamide and gliclazide and the glucosidase 15 inhibitors acarbose or miglitol or insulin (injectable, pulmonary, buccal, or oral) may be employed in formulations as described above and in amounts and dosing as indicated in the Physician's Desk Reference (PDR).

Where present, metformin or salt thereof may be 20 employed in amounts within the range from about 500 to about 2000 mg per day which may be administered in single or divided doses one to four times daily.

Where present, the PPAR anti-diabetic agent may be employed in amounts within the range from about 0.01 to 25 about 2000 mg/day which may be administered in single or divided doses one to four times per day.

Where present insulin and other anti-diabetic agents as set out above may be employed in formulations, amounts and dosing as indicated by the Physician's Desk 30 Reference.

Where present GLP-1 peptides or mimetics may be administered in oral buccal formulations, by nasal administration or parenterally as described in U.S. Patent Nos. 5,346,701 (TheraTech), 5,614,492 and 35 5,631,224 which are incorporated herein by reference.

The antidiabetic agent or other lipid agent may also be a PPAR modulator such as a PPAR α/γ dual agonist such as AR-H039242 (Astra/Zeneca), GW-409544 (Glaxo-Wellcome), KRP297 (Kyorin Merck) as well as those
5 disclosed by Murakami et al, "A Novel Insulin Sensitizer Acts As a Coligand for Peroxisome Proliferation - Activated Receptor Alpha (PPAR alpha) and PPAR gamma. Effect on PPAR alpha Activation on Abnormal Lipid Metabolism in Liver of Zucker Fatty Rats", Diabetes 47,
10 1841-1847 (1998), and in U.S. application Serial No. 09/664,598, filed September 18, 2000, (attorney file LA29) the disclosure of which is incorporated herein by reference, employing dosages as set out therein, which compounds designated as preferred are preferred for use
15 herein.

The antidiabetic agent may be an SGLT2 inhibitor such as disclosed in U.S. application Serial No. 09/679,027, filed October 4, 2000 (attorney file LA49), employing dosages as set out therein. Preferred are the
20 compounds designated as preferred in the above application.

The antidiabetic agent may be an aP2 inhibitor such as disclosed in U.S. application Serial No. 09/391,053, filed September 7, 1999, and in U.S.
25 application Serial No. 09/519,079, filed March 6, 2000 (attorney file LA27), employing dosages as set out herein. Preferred are the compounds designated as preferred in the above application.

The antidiabetic agent may be a DP4 inhibitor such
30 as disclosed in application Serial No. 09/788,173, filed February 16, 2001 (attorney file LA50), WO99/38501, WO99/46272, WO99/67279 (PROBIODRUG), WO99/67278 (PROBIODRUG), WO99/61431 (PROBIODRUG), NVP-DPP728A (1-
[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-
35 cyano-(S)-pyrrolidine) (Novartis) (preferred) as disclosed by Hughes et al, Biochemistry, 38(36), 11597-

11603, 1999, TSL-225 (tryptophyl-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid (disclosed by Yamada et al, Bioorg. & Med. Chem. Lett. 8 (1998) 1537-1540, 2-cyanopyrrolidides and 4-cyanopyrrolidides as disclosed by 5 Ashworth et al, Bioorg. & Med. Chem. Lett., Vol. 6, No. 22, pp 1163-1166 and 2745-2748 (1996) employing dosages as set out in the above references.

The meglitinide which may optionally be employed in combination with the compound of formula I of the 10 invention may be repaglinide or Starlix® (Novartis), nateglinide (Novartis) or KAD1229 (PF/Kissei), with repaglinide being preferred.

The antidiabetic compound may be a melanocortin receptor agonist such as a spiroperidine as disclosed 15 in WO 99/64002.

The HMG CoA reductase inhibitor of formula I will be employed in a weight ratio to the meglitinide, PPAR modulator such as a PPAR γ agonist, PPAR α agonist, PPAR δ agonists or antagonist, PPAR α/γ dual agonist, aP2 20 inhibitor, DP4 inhibitor or SGLT2 inhibitor or other antidiabetic agent within the range from about 0.01:1 to about 100:1, preferably from about 0.05:1 to about 10:1.

The other type of therapeutic agent which may be optionally employed with the HMG CoA reductase inhibitor 25 of formula I may be 1, 2, 3 or more of an anti-obesity agent including a beta 3 adrenergic agonist, a lipase inhibitor, a serotonin (and dopamine) reuptake inhibitor, an aP2 inhibitor, a thyroid receptor beta drug, a PTP-1B inhibitor, an anorectic agent, a PPAR modulator including 30 PPAR γ antagonists, PPAR α agonists, PPAR δ antagonists, a CCKA agonist, a leptin inhibitor such as a leptin receptor activator, a neuropeptide Y antagonist, a melanocortin-4-receptor (MC4R) agonist, a fatty acid oxidation upregulator or inducer (such as Famoxin® 35 Genset).

The beta 3 adrenergic agonist which may be optionally employed in combination with a compound of formula I may be AJ9677 (Takeda/Dainippon), L750355 (Merck), or CP331648 (Pfizer) or other known beta 3
5 agonists as disclosed in U.S. Patent Nos. 5,541,204, 5,770,615, 5,491,134, 5,776,983 and 5,488,064, with AJ9677, L750,355 and CP331648 being preferred.

The neuropeptide Y antagonists which may be optionally employed in combination with a compound of formula I include those described in WO 0113917 (BMS) or
10 in U.S. Patent No. 6,218,408 (Synaptic) and in WO 0114376 (Banyu).

The lipase inhibitor which may be optionally employed in combination with a compound of formula I may
15 be orlistat or ATL-962 (Alizyme), with orlistat being preferred.

The serotonin (and dopamine) reuptake inhibitor which may be optionally employed in combination with a compound of formula I may be sibutramine, topiramate
20 (Johnson & Johnson) or axokine (Regeneron), with sibutramine and topiramate being preferred.

The thyroid receptor beta compound which may be optionally employed in combination with a compound of formula I may be a thyroid receptor ligand as disclosed
25 in WO97/21993 (U. Cal SF), WO99/00353 (KaroBio), GB98/284425 (KaroBio), and U.S. Provisional Application 60/183,223 filed February 17, 2000, with compounds of the KaroBio applications and the above U.S. provisional application being preferred.

30 The anorectic agent which may be optionally employed in combination with a compound of formula I may be dexamphetamine, phentermine, phenylpropanolamine or mazindol, with dexamphetamine being preferred.

The CCKA agonists which may be employed herein include Glaxo-SmithKline's GI-181,771 and Sanofi's SR146,131.

5 The PTP-1B inhibitor which may be an anti-oesity and/or an antidiabetic agent include those disclosed in WO 99/585,521, WO 99/58518, WO 99/58522 and WO 99/61435.

The anti-obesity agent employed may also be Pfizer's P57 or CP-644,673 (licensed from Phytopharm).

10 The various anti-obesity agents described above may be employed in the same dosage form with the compound of formula I or in different dosage forms, in dosages and regimens as generally known in the art or in the PDR.

15 The antihypertensive agents which may be employed in combination with the HMG CoA reductase inhibitors of the invention include ACE inhibitors, angiotensin II receptor antagonists, NEP inhibitors such as candoxatril, NEP/ACE inhibitors, as well as calcium channel blockers (such as verapamil and amlodipine besylate), T-channel calcium antagonists (such as mibefradil), β -adrenergic 20 blockers, diuretics, α -adrenergic blockers (such as doxazosin mesylate and terazosin HCl), dual action receptor antagonists (DARA), heart failure drugs such as digoxin, and other types of antihypertensive agents.

25 The angiotensin converting enzyme inhibitor which may be employed herein includes those containing a mercapto (-S-) moiety such as substituted proline derivatives, such as any of those disclosed in U.S. Pat. No. 4,046,889 to Ondetti et al mentioned above, with captopril, that is, 1-[(2S)-3-mercaptop-2-30 methylpropionyl]-L-proline, being preferred, and mercaptoacyl derivatives of substituted prolines such as any of those disclosed in U.S. Pat. No. 4,316,906 with zofenopril being preferred.

Other examples of mercapto containing ACE inhibitors that may be employed herein include rentiapril (fentiapril, Santen) disclosed in Clin. Exp. Pharmacol. Physiol. 10:131 (1983); as well as pivopril and YS980.

- 5 Other examples of angiotensin converting enzyme inhibitors which may be employed herein include any of those disclosed in U.S. Pat. No. 4,374,829 mentioned above, with N-(1-ethoxycarbonyl-3-phenylpropyl)-L-alanyl-L-proline, that is, enalapril, being preferred, any of
- 10 the phosphonate substituted amino or imino acids or salts disclosed in U.S. Pat. No. 4,452,790 with (S)-1-[6-amino-2-[[hydroxy-(4-phenylbutyl)phosphinyl]oxy]-1-oxohexyl]-L-proline or (ceronapril) being preferred, phosphinylalkanoyl prolines disclosed in U.S. Pat. No.
- 15 4,168,267 mentioned above with fosinopril being preferred, any of the phosphinylalkanoyl substituted prolines disclosed in U.S. Pat. No. 4,337,201, and the phosphonamides disclosed in U.S. Pat. No. 4,432,971 discussed above.
- 20 Other examples of ACE inhibitors that may be employed herein include Beecham's BRL 36,378 as disclosed in European Patent Application Nos. 80822 and 60668; Chugai's MC-838 disclosed in C.A. 102:72588v and Jap. J. Pharmacol. 40:373 (1986); Ciba-Geigy's CGS 14824 (3-([1-ethoxycarbonyl-3-phenyl-(1S)-propyl]amino)-2,3,4,5-tetrahydro-2-oxo-1-(3S)-benzazepine-1 acetic acid HCl) disclosed in U.K. Patent No. 2103614 and CGS 16,617 (3(S)-[(1S)-5-amino-1-carboxypentyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-ethanoic acid)
- 25 30 disclosed in U.S. Pat. No. 4,473,575; cetapril (alacepril, Dainippon) disclosed in Eur. Therap. Res. 39:671 (1986); 40:543 (1986); ramipril (Hoechsst) disclosed in Euro. Patent No. 79-022 and Curr. Ther. Res. 40:74 (1986); Ru 44570 (Hoechst) disclosed in Arzneimittelforschung 34:1254 (1985), cilazapril

(Hoffman-LaRoche) disclosed in J. Cardiovasc. Pharmacol. 9:39 (1987); R 31-2201 (Hoffman-LaRoche) disclosed in FEBS Lett. 165:201 (1984); lisinopril (Merck), indalapril (delapril) disclosed in U.S. Pat. No. 4,385,051;

5 indolapril (Schering) disclosed in J. Cardiovasc. Pharmacol. 5:643, 655 (1983), spirapril (Schering) disclosed in Acta. Pharmacol. Toxicol. 59 (Supp. 5):173 (1986); perindopril (Servier) disclosed in Eur. J. clin. Pharmacol. 31:519 (1987); quinapril (Warner-Lambert)

10 disclosed in U.S. Pat. No. 4,344,949 and CI925 (Warner-Lambert) ([3S-[2[R(*)]R(*)]]3R(*)]-2-[2-[[1-(ethoxy-carbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid HCl) disclosed in Pharmacologist 26:243, 266 (1984), WY-

15 44221 (Wyeth) disclosed in J. Med. Chem. 26:394 (1983).

Preferred ACE inhibitors are captopril, fosinopril, enalapril, lisinopril, quinapril, benazepril, fentiapril, ramipril and moexipril.

NEP/ACE inhibitors may also be employed herein in

20 that they possess neutral endopeptidase (NEP) inhibitory activity and angiotensin converting enzyme (ACE) inhibitory activity. Examples of NEP/ACE inhibitors suitable for use herein include those disclosed in U.S. Pat. No.s. 5,362,727, 5,366,973, 5,225,401, 4,722,810,

25 5,223,516, 4,749,688, U.S. Patent. No. 5,552,397, U.S. Pat. No. 5,504,080, U.S. Patent No. 5,612,359, U.S. Pat. No. 5,525,723, European Patent Application 0599,444, 0481,522, 0599,444, 0595,610, European Patent Application 0534363A2, 534,396 and 534,492, and European Patent

30 Application 0629627A2.

Preferred are those NEP/ACE inhibitors and dosages thereof which are designated as preferred in the above patents/applications which U.S. patents are incorporated herein by reference; most preferred are omapatrilat,

35 gemopatrilat ([S[(R*,R*)]-hexahydro-6-[(2-mercaptopro-1-oxo-

3-phenylpropyl)amino]-2,2-dimethyl-7-oxo-1H-azepine-1-acetic acid) and CGS 30440.

The angiotensin II receptor antagonist (also referred to herein as angiotensin II antagonist or AII 5 antagonist) suitable for use herein includes, but is not limited to, irbesartan, losartan, valsartan, candesartan, tasosartan or eprosartan, with irbesartan, losartan or valsartan being preferred.

A preferred oral dosage form, such as tablets or 10 capsules, will contain the ACE inhibitor or AII antagonist in an amount within the range from about 0.1 to about 500 mg, preferably from about 5 to about 200 mg and more preferably from about 10 to about 150 mg.

For parenteral administration, the ACE inhibitor, 15 angiotensin II antagonist or NEP/ACE inhibitor will be employed in an amount within the range from about 0.005 mg/kg to about 10 mg/kg and preferably from about 0.01 mg/kg to about 1 mg/kg.

Where a drug is to be administered intravenously, 20 it will be formulated in conventional vehicles, such as distilled water, saline, Ringer's solution or other conventional carriers.

It will be appreciated that preferred dosages of 25 ACE inhibitor and AII antagonist will be as set out in the latest edition of the Physician's Desk Reference (PDR).

Dual action receptor antagonists (DARA) suitable for use herein include those disclosed in U.S. applications Serial No. 09/513,779, filed February 25, 30 2000, and Serial No. 09/604,322, filed June 26, 2000.

Other examples of preferred antihypertensive agents suitable for use herein include omapatrilat (Vanlev®), gemopatrilat, amlodipine besylate (Norvasc®), prazosin HCl (Minipress®), verapamil, nifedipine, diltiazem,

felodipine, nisoldipine, isradipine, nicardipine, beta blockers such as nadolol, atenolol (Tenormin®), sotalol, terazosin, doxazosin, carvedilol, and propranolol, and clonidine HCl (Catapres®).

5 Diuretics which may be employed in combination with compounds of formula I include hydrochlorothiazide, torasemide, furosemide, spironolactone, and indapamide.

Antiplatelet agents which may be employed in combination with compounds of formula I of the invention 10 include aspirin, clopidogrel, ticlopidine, dipyridamole, abciximab, tirofiban, eptifibatide, anagrelide, and ifetroban, with clopidogrel and aspirin being preferred.

The antihypertensive agents, diuretics and antiplatelet drugs may be employed in amounts as 15 indicated in the PDR. Ifetroban may be employed in amounts as set out in U.S. Patent No. 5,100,889.

Anti-Alzheimer's agents or anti-dementia agents suitable for use herein with the HMG CoA reductase inhibitors of the invention include tacrine HCl (Cognex®) 20 and donepezil (Aricept®), as well as γ -secretase inhibitors, β -secretase inhibitors and/or antihypertensive agents. Dosages employed will be as set out in the PDR.

Antosteoporosis agents suitable for use herein in 25 combination with the HMG CoA reductase inhibitors of the invention include parathyroid hormone or bisphosphonates, such as MK-217 (alendronate) (Fosamax®) as well as Ca receptor agonists and progestin receptor agonists. Dosages employed will be as set out in the PDR.

30 The hormone replacement therapeutic agents, where present, will be employed in dosages as set out in the latest edition of the PDR. Examples of such agents include selective estrogen receptor modulators (SERMs) such as raloxifene, tamoxifene or lasoxifene.

The HMG CoA reductase compound of the invention may also be employed in combination with a tyrosine kinase inhibitor such as disclosed in WO 2000/053605;

5 the selective androgen receptor modulator suitable for use herein may be LGD-2226 (Ligand);

the antiarrhythmic agents suitable for use herein include β-blockers as set out herein including sotalol and amioderone, calcium channel blockers as set out herein including verapamil, nifedipine, amlodipine-
10 besylate, and diltiazem, which may also be used in combination with a defibrillator device such as a pace maker;

coenzyme Q sub. 10 such as disclosed in U.S. Patent No. 5,316,765, 4,933,165, 4,929,437;

15 an agent that upregulates type III endothelial cell nitric acid syntase such as disclosed in WO 2000/003746;

a chondroprotective compound such as a polysulfated glycosaminoglycan (PSGAG), glucosamine, chondroitin sulfate (CS), hyaluronic acid (HA), pentosan polysulfate
20 (PPS), doxycycline or minocycline, such as disclosed in EP 970694;

a cyclooxygenase (COX)-2 inhibitor, such as celecoxib (Celebrex® (Searle)) or rofecoxib (Vioxx® (Merck)) or a glycoprotein IIa/IIIb receptor antagonist
25 such as disclosed in WO 99/45913 and tirofiban or abciximab;

a 5-HT reuptake inhibitor such as disclosed in WO 99/44609;

30 anti-anginal agents such as vasodilators, for example, isosorbide dinitrate, or nitroglycerin;

a growth hormone secretagogue such as disclosed in U.S. applications Serial No. 09/662,448, filed September 14, 2000, and U.S. Provisional application 60/203,335, filed May 11, 2000, and MK-677 (Merck), Pfizer's CP-
35 424391 and Lilly's LY 444,711;

- anti-atherosclerosis agents such as ACAT inhibitors and lipoxygenase inhibitors as described herein and phospholipase A-2 inhibitors such as S-3013 and SB-435,495 (which are also anti-inflammatory agents);
- 5 anti-infective agents such as quinolones, for example, ciprofloxacin, ofloxacin, and Tequin® (Bristol-Myers Squibb), macrolides such as erythromycin and clarithromycin (Biaxin® (Abbott)), and azithromycin (Zithromax (Pfizer)); or
- 10 an immunosuppressant (for use in transplantations) such as cyclosporine, mycophenolate mofetil, azathioprine and the like.

As used herein, the phrase "antineoplastic agent" refers to compounds which prevent cancer cells from multiplying. In general, the antineoplastic agents used herein prevent cancer cells from multiplying by: (1) interfering with the cell's ability to replicate DNA, or (2) inducing apoptosis in the cancerous cells.

Examples of antineoplastic agents which are suitable for use in combinations of this invention include, but are not limited to, microtuble-stabilizing agents such as the taxanes, for example, paclitaxel (also known as Taxol®), docetaxel (also known as Taxotere®), 7-O-methylthio- methylpaclitaxel (disclosed in U.S. 5,646,176), 3'-tert-butyl-3'-N-tert-butyloxycarbonyl-4-deacetyl-3'-dephenyl-3'-N-debenzoyl-4-O-methoxycarbonyl-paclitaxel (disclosed in USSN 60/179,965 filed on February 3, 2000, and example 17 herein), C-4 methyl carbonate paclitaxel (disclosed in WO 94/14787), the epothilone, such as epothilone A, epothilone B, epothilone C, epothilone D, desoxyepothilone A, desoxyepothilone B, [1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-4-aza-17-oxabicyclo[4.1.0]heptadecane-5,9-dione (disclosed in WO 99/02514), [1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-[2-

(aminomethyl)-4-thiazolyl]-1-methylethenyl]-7,11-di-hydroxy-8,8,10,12,16-pentamethyl-4,17-dioxabi-cyclo[14.1.0]-heptadecane-5,9-dione (disclosed in USSN 09/506,481 filed on February 17, 2000, and examples 7 and 8 herein), and derivatives thereof; microtubule-disruptor agents; alkylating agents; anti-metabolites; epidophyllotoxin; an antineoplastic enzyme; a topoisomerase inhibitor; procarbazine; mitoxantrone; platinum coordination complexes; biological response modifiers; growth inhibitors; hormonal/antihormonal therapeutic agents; and haematopoietic growth factors.

Other classes of antineoplastic agents suitable for use in the method of the present invention include, but are not limited to, the anthracycline family of drugs, the vinca drugs, the mitomycins, the bleomycins, the cytotoxic nucleosides, discodermolide, the pteridine family of drugs, diynenes, aromatase inhibitors, and the podophyllotoxins. Particularly useful members of those classes not previously mentioned include, for example, doxorubicin, carminomycin, daunorubicin, aminopterin, methotrexate, methopterin, dichloro-methotrexate, mitomycin C, porfiromycin, 5-fluorouracil, 6-mercaptopurine, gemcitabine, cytosine arabinoside, podophyllotoxin or podophyllotoxin derivatives such as etoposide, etoposide phosphate or teniposide, melphalan, vinblastine, vincristine, leurosidine, vindesine, leurosine, and the like. Other useful antineoplastic agents include estramustine, cisplatin, carboplatin, cyclophosphamide, bleomycin, tamoxifen, ifosfamide, melphalan, hexamethyl melamine, thiotapec, cytarabin, idatrexate, trimetrexate, dacarbazine, L-asparaginase, camptothecin, CPT-11, topotecan, ara-C, bicalutamide, flutamide, leuprolide, pyridobenzoindole derivatives, interferons, and interleukins.

It will be appreciated that unless otherwise specified the dosage regimen for therapeutic agents used

in combination with the compounds of the invention will be as specified in the PDR.

In carrying out the method of the invention for treating hypercholesterolemia, hyperlipidemia, 5 hyperlipoproteinemia, hypertriglyceridemia, or atherosclerosis, and related diseases, or Alzheimer's disease or osteoporosis, or other disclosures as set out hereinbefore, a pharmaceutical composition will be employed containing the compounds of structure I, with or 10 without other cholesterol lowering agents, osteoporosis agents, Alzheimer's agents, antidiabetic agent(s) and/or antihyperlipidemic agent(s) and/or other type therapeutic agents in association with a pharmaceutical vehicle or diluent. The pharmaceutical composition can be 15 formulated employing conventional solid or liquid vehicles or diluents and pharmaceutical additives of a type appropriate to the mode of desired administration, such as pharmaceutically acceptable carriers, excipients, binders and the like. The compounds can be administered 20 to mammalian species including humans, monkeys, dogs, etc. by an oral route, for example, in the form of tablets, capsules, beads, granules or powders, or they can be administered by a parenteral route in the form of injectable preparations, or they can be administered 25 intranasally or in transdermal patches. Typical solid formulations will contain from about 0.1 to about 500 mg of a compound of formula I. The dose for adults is preferably between 0.5 and 1,000 mg per day, which can be administered in a single dose or in the form of 30 individual doses from 1-4 times per day and also single dose once weekly (5 to 1000 mg).


A typical injectable preparation is produced by aseptically placing 250 mg of compounds of structure I into a vial, aseptically freeze-drying and sealing. For 35 use, the contents of the vial are mixed with 2 mL of physiological saline, to produce an injectable preparation.

The following abbreviations are employed in the Examples and elsewhere herein:


- 5 Ph = phenyl
Bn = benzyl
i-Bu = iso-butyl
Me = methyl
Et ethyl
10 TMS = trimethylsilyl
FMOC = fluorenylmethoxycarbonyl
Boc = tert-butoxycarbonyl
Cbz = carbobenzyloxy or carbobenzoxy or benzyloxycarbonyl
DIPEA = diisopropyl ethylamine
15 PTSH = N-phenylthiotetrazole
PPh₃ = triphenylphosphine
NMO = methyldmorpholine N-oxide
TPAP = tetrapropylammonium perruthenate
DEAD = diethyl azodicarboxylate
20 HOAc or AcOH = acetic acid
TFA = trifluoroacetic acid
Et₂NH = diethylamine
NMM = N-methyl morpholine
n-BuLi = n-butyllithium
25 Pd/C = palladium on carbon
PtO₂ = platinum oxide
MTBE = methyl t-butyl ether
DI water = dionized water
TEA = triethylamine
30 EDAC = 3-ethyl-3'-(dimethylamino)propyl-carbodiimide hydrochloride (or 1-[(3-(dimethyl)amino)propyl])-3-ethylcarbodiimide hydrochloride)
HOBT or HOBT.H₂O = 1-hydroxybenzotriazole hydrate
HOAT = 1-hydroxy-7-azabenzotriazole
35 PyBOP reagent = benzotriazol-1-yloxy-tripyrrolidino phosphonium hexafluorophosphate
LiN(TMS)₂ = Libis(trimethylsilyl)amide

DIBAL = diisobutylaluminum hydride
LDA = lithium diisopropylamide
DMPU = 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone
AcCN = acetonitrile
5 LiHMDS = lithium bis(trimethylsilyl)amide
NaHMDS = sodium bis(trimethylsilyl)amide
Red-AL = sodium bis(2-methoxyethoxy)aluminum hydride
mCPBA = m-chloro-p-benzoic acid
min = minute(s)
10 h or hr = hour(s)
L = liter
mL = milliliter
 μ L = microliter
g = gram(s)
15 mg = milligram(s)
mol = moles
mmol = millimole(s)
meq = milliequivalent
RT, rt = room temperature
20 sat or sat'd = saturated
aq. = aqueous
TLC = thin layer chromatography
HPLC = high performance liquid chromatography
LC/MS = high performance liquid chromatography/mass
25 spectrometry
MS or Mass Spec = mass spectrometry
NMR = nuclear magnetic resonance
mp = melting point
Bp = boiling point
30

The following Examples represent preferred embodiments of the invention. Unless otherwise indicated, all temperatures are in degrees Centigrade.

Example 1

A.




5

To a slurry of NaH (19.20 g, 480 mmol) and diethyl carbonate (80 mL) in a 3-neck 1L round bottom flask at room temperature was added a solution of cyclopropyl methylketone (23.5 mL, 238 mmol) in Et₂O (30 mL).

- 10 Approximately 10% of the solution was added, and then 0.25 mL of EtOH was added to the reaction slurry. Addition of the remaining ketone solution continued with light gas evolution. After addition of all of the ketone solution, the reaction became quite exothermic with
- 15 vigorous H₂ evolution. The reaction mixture was cooled periodically with an ice-bath to keep the temperature around 35°C to 50°C. After one hour, gas evolution had ceased and the reaction mixture was stirred at room temperature for 2h. The reaction mixture was cooled in an ice-bath, diluted with Et₂O (200 mL), and treated with 1 N HCl with some ice to adjust to around pH 3. The reaction mixture was extracted with Et₂O (3 x 150 mL). The Et₂O extracts were combined, washed with saturated aqueous NaHCO₃ (200 mL), H₂O (200 mL) and brine (200 mL), and dried (Na₂SO₄), filtered and concentrated under reduced pressure to give a yellow oil. The oil was distilled under vacuum to give the title compound as a colorless oil, 28.5 g, 77%. B.p. = 94-96°C/8 mmHg.


B.



To a stirred solution of Part A compound (28.24 g, 181 mmol) in benzene (128 mL) was added 4-fluorobenzaldehyde (19.4 mL, 181 mmol), HOAc (0.31 mL, 5.4 mmol) and piperidine (1.8 mL, 18.2 mL). The reaction mixture was heated at reflux and azeotrope was collected with a Dean-Stark trap. After 16 h, the reaction was cooled to room temperature, diluted with Et₂O (250 mL), washed with aqueous 0.5 N HCl, saturated aqueous NaHCO₃, H₂O and brine, and then dried (Na₂SO₄), filtered and concentrated under reduced pressure. Purification by flash chromatography (1:10 EtOAc/hexane) gave the title compound as a light yellow oil, 29 g, 61% yield.

15

C.




To a solution of 1-benzosuberone (7.35 g, 45.9 mmol) in THF (3 mL) at -78°C under N₂ was added a solution of lithium bis(trimethylsilyl)amide (1 M in THF, 40.5 mL, 40.5 mmol). The reaction mixture was stirred at -78°C for 1 h, then a solution of Part B compound (7.07 g, 26.95 mmol) in THF (3 mL) was added dropwise. The reaction mixture was stirred at -78°C for 1 h, then at 0°C for 30 min. The reaction mixture was quenched with HOAc (8 mL) and poured into saturated aqueous NH₄Cl (250 mL), then extracted with Et₂O (3 x 60 mL). The combined Et₂O extracts were washed with H₂O and brine, then dried

(Na₂SO₄), filtered and concentrated *in vacuo* to give the title compound as a light yellow oil. The resulting crude product was used in the next step without further purification.


5

D.




To a stirred solution of crude Part C compound (26.9 mmol) in HOAc (128 mL) was added ammonium acetate (9.14 g, 118.6 mmol) and copper (II) acetate monohydrate (19.7 g, 99.7 mmol). The reaction mixture was heated at reflux under argon overnight. After cooling to room temperature, the reaction mixture was poured into a mixture of NH₄OH (150 mL) and ice (~300 g), then extracted with Et₂O (3 x 100 mL). The combined Et₂O extracts were washed with H₂O and brine, then dried (Na₂SO₄), filtered and concentrated *in vacuo*. Purification by flash chromatography (2:20:80-EtOAc/CH₂Cl₂/hexane) gave the title compound as a white foam, 7.7 g, 71% yield (from Part B compound).

E.



- To a stirred solution of Part D compound (7.7 g, 19.2 mmol) in THF (30 mL) at 0°C under argon was added a 5 solution of lithium aluminum hydride (1 M in THF, 60 mL, 60 mmol) at a rate to maintain the temperature below 10°C. After addition, the reaction mixture was stirred at room temperature for 1.5 h and cooled to 0°C, then carefully quenched with H₂O (15mL), 10% aqueous NaOH (15 10 mL) and H₂O (15mL). The reaction mixture was stirred at room temperature for 15 minutes and filtered. The solid was washed with Et₂O and EtOAc. The combined organic extracts/washings were washed with H₂O and brine, then dried (Na₂SO₄), filtered and concentrated *in vacuo*.
- 15 Recrystallization from EtOAc-hexane gave the title compound as a white solid, 5.25 g, 76% yield.

F.




- 20 To a slurry of Part E compound (5.2 g, 14.5 mmol) in CH₂Cl₂ (40 mL) at 0°C under argon was added a solution of PBr₃ (29 mL, 29 mmol) in CH₂Cl₂, dropwise, maintaining the temperature between 0 to 10°C. After addition, the reaction mixture was stirred at 0°C for 1 h, then

quenched with saturated aqueous NaHCO_3 (100 mL) and extracted with EtOAc (3 x 80 mL). The combined organic extracts were washed with H_2O and brine, then dried (Na_2SO_4), filtered and concentrated *in vacuo*.

- 5 Purification by flash chromatography (1:3 CH_2Cl_2 /hexane) gave the title compound as a white powder, 3.85 g, 63% yield.


G.



10


- A solution of diethyl phosphite (1.50 g, 10.9 mmol) in THF (10 mL) was cooled to -10°C under argon and then a solution of sodium bis (trimethylsilyl)amide (1 M in THF, 10.7 mL, 10.7 mmol) was added, dropwise. The reaction mixture was stirred at -10°C for 30 min, and then a solution of Part F compound (3.82 g, 9.05 mmol) in THF (15 mL) was added maintaining temperature around -10 to 0°C . The reaction mixture was stirred at -10°C for 1 h. The reaction mixture was quenched with saturated aqueous NH_4Cl (150 mL), then extracted with EtOAc (3 x 100 mL). Combined EtOAc extracts were washed with saturated aqueous NH_4Cl (150 mL), H_2O and brine, then dried (Na_2SO_4), filtered and concentrated *in vacuo*. Purification by flash chromatography (1:2-EtOAc:hexane) gave the title compound as a white foam, 4.1 g, 94% yield.

H.



A flame-dried 200 mL round bottom flask was charged with Part G compound (2.062 g, 4.3 mmol) and 5 chased with anhydrous toluene (2 x 10 mL), then dried on high vacuum and purged with argon. The residue was dissolved in THF (15 mL) and cooled to -78°C under argon. A solution of nBuLi (2.4 M in hexanes, 1.90 mL, 4.52 mmol) was added dropwise, maintaining the temperature 10 around -78 to -74°C. A solution of the Example 2 Part G aldehyde compound (1.332 g, 5.16 mmole) in THF (10 mL) was added dropwise. The reaction mixture was stirred at -78°C for 40 min, at -10°C for 1h, and at room temperature for 1h. The reaction mixture was quenched with saturated 15 aqueous NH₄Cl (100 mL), then extracted with EtOAc (2 x 100 mL). Combined EtOAc layers were washed with H₂O and brine, then dried (Na₂SO₄), filtered and concentrated *in vacuo*. Purification by flash chromatography (27:973-EtOAc:CH₂Cl₂) gave the title compound as a white foam, 804 20 mg, 34% yield.


I.



To a solution of part H compound (804 mg, 1.38 mmol) in CH₂Cl₂ (18 mL) at 0°C under argon was added trifluoroacetic acid (1.59 mL, 20.7 mmol). The reaction mixture was stirred at room temperature for 5h, diluted 5 with EtOAc (100 mL) and washed with saturated aqueous NaHCO₃ (60 mL x 2), H₂O and brine, then dried (Na₂SO₄), filtered and concentrated *in vacuo*. Purification by flash chromatography (45:55-EtOAc:hexane) gave the title compound as a white foam, 540 mg, 83% yield.

10


J.



To a solution of Part I compound (515 mg, 1.1 mmol) in THF (10 mL) was added 1N aqueous NaOH (1.37 mL, 15 1.37 mmol) and stirred at room temperature for 10 min. The reaction mixture was concentrated *in vacuo* and purified by SP207 (Na⁺ form) resin, eluting with 3:7-H₃CN:H₂O. The desired fractions were pooled and lyophilized to give the title compound as a white powder, 20 506 mg, 91% yield. LRMS gave the correct molecular ion [(M - Na⁺ + 2H⁺) = 488] for the desired compound.

Example 1AAlternate Procedure for Example 1 Part H compound


(1).



5

To a stirred solution of Example 1 Part E compound (13.07 g, 31.0 mmol) in toluene (300 mL) was added O-ethyl diphenylphosphinate (8.65 mL, 40.0 mmol) in one portion. The reaction was heated to reflux, using a Dean-Stark trap to remove the ~15 mL of solvent. After 2h, the solution was cooled and evaporated to nearly remove all of the solvent. The residue was triturated in hexanes (~100 mL), the resulting solids were collected and dried in vacuo at 60°C to give Part (1) compound as a white solid, 15.25 g, 91% yield, mp 201-203°C.

(2).




A 1 L 3-necked round bottom flask was flame-dried and then fitted with a mechanical stirrer, an argon-filled balloon, vacuum take-off and a thermocouple. To a stirred slurry of Part (1) compound (7.00 g, 12.9 mmol) in THF (200 mL) at 0°C was added n-butyllithium solution (5.4 mL, 2.5 M in hexanes, 13.5 mmol) over 20 min. A


deep red-orange solution formed. After 30 min, a solution of zinc chloride-N,N,N',N'-tetramethylethylenediamine complex (dried *in vacuo* at 60°C for 2h, 3.42 g, 13.5 mmol) in THF (100 mL) was added *via* cannula and 5 stirred 30 min. After 30 min, the resulting solution was cannulated into a solution of Example 2 Part G aldehyde (4.30 g, 16.6 mmol) in THF (20 mL) at room temperature over 20 min. A light orange solution soon formed, followed by a precipitate. After 3 h, the reaction was 10 quenched with brine (50 mL) and water (50 mL) and extracted three times with ethyl acetate (100 mL). The organic extracts were combined, dried ($MgSO_4$) and evaporated. LCMS of the crude material indicated unreacted Part (1) compound and an 89/11 mixture of the 15 desired (E) isomer/undesired (Z) isomer.

The reaction was repeated and the combined crude product (28 g) was purified by flash chromatography on silica gel in two identical batches (12 x 22 cm column, 1.5 L 1:99 EtOAc/CH₂Cl₂, 2 L 1:39 EtOAc/CH₂Cl₂ and then 1.5 20 L 3:7 EtOAc/hexanes). Partially pure E/Z mixtures were pooled and repurified to give the title Part (2) compound (which is the same as Example 1 Part H compound) (99.2% 25 (E) isomer) as a crystalline solid (after evaporation from toluene), mp 146-147°C, 7.14 g (68% yield, based on recovered Part (1) compound).

Example 2




A.



To a solution of 4-fluoro-benzaldehyde (5g, 40.3 mmol) and ethyl isobutyryl acetate (6.5 mL, 40.3 mmol) in benzene (50 mL) was added piperidine (400 μ L, 4.04 mmol), followed by acetic acid (100 μ L, 1.66 mmol). The reaction was refluxed for 16 hours and partitioned between aqueous HCl (1N, 20 mL) and ethyl acetate (50 mL \times 2). The combined organic layers were washed with saturated NaHCO₃ (20 mL), brine (10 mL), and dried over sodium sulfate (Na₂SO₄). The solvent was removed *in vacuo*. Distillation at 140°C at 300 mm Hg afford 9.06 g (85% yield) of compound A as a yellow oil. ESI-LC/MS (M+H)⁺ = 264.


B.



To a 1M lithium hexamethyldisazide solution (50 mL, 50 mmol) at -78°C under N₂ was added a THF (3 mL) solution of benzosuborone (9 g, 56.1 mmol). The reaction temperature was maintained below -75°C during the addition. The reaction was then stirred at -78°C for 1 hour and compound A (9 g, 34.1 mmol, in 3 mL THF) was slowly added to the reaction. After the addition was complete, the reaction was stirred for 1 hour at -74°C then warmed to 0°C and stirred for 20 minutes. The reaction was quenched with HOAc (9 mL) and poured into saturated ammonium chloride solution (NH₄Cl, 20 mL). The aqueous layer was extracted with ethyl ether (100 mL \times

3). The combined organic layers were washed with water (30 mL) and brine (30 mL), then dried over sodium sulfate (Na_2SO_4). The solvent was removed *in vacuo* and stripped with toluene twice to afford crude compound B. The crude 5 compound B was used directly in the next step. ESI-LC/MS $(\text{M}+\text{H})^+ = 425$.

C.



10

To a solution of the crude compound B (12 g) in aqueous HOAc (100 mL) was added ammonium acetate (9.5g, 123.2 mmol), followed by cupric acetate monohydrate (20.7g, 113.9 mmol). The reaction was reflux for 20 15 hours, cooled to room temperature, then poured into a solution of ammonium hydroxide in ice (1 to 1; v/v). The aqueous layer was extracted with ethyl ether (200 mL x 3). The combined organic layers were washed with water (50 mL) and brine (50 mL). Flash chromatography (10% 20 ethyl acetate in hexane) afforded 10.2 g (88% yield) of compound C as white powder. ESI-LC/MS $(\text{M}+\text{H})^+ = 404$; m.p. 138-140°C.

D.




25

To a solution of compound C (10 g, 24.78 mmol) in anhydrous THF (240 mL) at 0°C was added 1.0 M lithium aluminum hydride in THF (74 mL, 74 mmol). The reaction 30 was stirred at 0°C for 1 hour and then warmed to room temperature and stirred for 16 hours. The reaction was


then cooled to 0°C and quenched slowly with ice, then sodium hydroxide (10% NaOH, 20 mL). The mixture was extracted with diethyl ether (50 mL x 2) and filtered. The filter cake was then washed with more ethyl ether (10 mL) and ethyl acetate (10 mL). The combined organic layers were washed with water (10 mL) and brine (10 mL), then dried over sodium sulfate (Na_2SO_4). Flash chromatography (20% ethyl acetate in hexane) afforded 6.5 g (73% yield) of compound D. ESI-LC/MS ($\text{M}+\text{H})^+ = 362$; m.p. 10 170-171°C.

E.



15 To a solution of compound D (8.5 g, 23.54 mmol) in anhydrous CH_2Cl_2 (100 mL) at 0°C was slowly added 1.0 M phosphorous tribromide in CH_2Cl_2 (47 mL, 47.1 mmol) while maintaining the temperature below 10°C. After the addition was complete, the reaction was stirred at 0°C for 20 1 hour and then poured into saturated cold NaHCO_3 solution (200mL) with stirring. The aqueous layer was extracted with CH_2Cl_2 (50ml x 2) and the combined organic layer was washed with water (10 mL) and brine (10 mL), then dried over sodium sulfate (Na_2SO_4). Flash chromatography (10% 25 ethyl acetate in hexane) gave 8.6 g (86% yield) of compound E as a white solid. ESI-LC/MS ($\text{M}+\text{H})^+ = 424$; m.p. 157-159°C.


F.



To a solution of diethyl phosphite (785 μ L, 6.09 mmol) in anhydrous THF (25 mL) at -10°C under argon was added a 1.0 M THF solution of sodium hexamethyldisazide (6 mL, 6.09 mmol). The reaction mixture was stirred at -10°C for 30 minutes. A solution of compound E (2.15g, 5.08 mmol) in THF was added to the reaction while maintaining the temperature at -10°C. After the addition was complete, the reaction was stirred for 1 hour and quenched with water (20mL). The aqueous layer was extracted with ethyl acetate (30mL x 2) and the combined organic layers were washed with 1N HCl solution (5mL). The organic solvent was removed *in vacuo*. Flash chromatography using 20% to 30% ethyl acetate in hexane as eluting afforded 2.29 g (94% yield) of compound F as a white solid. ESI-LC/MS ($M+H$)⁺=482; m.p. 102-105°C.

20

G.



An oven-dried 3-neck 1-L flask equipped with temperature sensor probe, 125-mL constant pressure addition funnel and septum was charged with dry CH_2Cl_2 (300 mL) and dry DMSO (20.9 mL, 0.2944 mol, 2.5 equiv) under argon atmosphere; cooled to -7°C. Added neat oxalyl chloride (13.6 mL, 0.156 mol, 1.32 equiv) via syringe dropwise over 15 min (temperature rose to -66°C), then let stir additional 15 min. A solution of the starting alcohol 2-[(4R,6S)-6-(hydroxymethyl)-2,2-dimethyl-1,3-dioxan-4-yl]acetic acid t-butyl ester (30.66 g, 0.1178


mol, 1 equiv) in dry CH_2Cl_2 (80 mL) was added dropwise from the addition funnel over 30 min (temperature rose to -68°C). The resulting white mixture was stirred for 70 min at -76°C , then added triethylamine (82 mL, 0.5889 mol, 5 5 equiv) dropwise from addition funnel over 35 min (temperature rose to -65°C), then stirred the light yellow mixture vigorously at -76°C . TLC (SiO_2 , 20% EtOAc/ CH_2Cl_2 , $R_f=0.52$). After 30 min, removed the cooling bath and quenched the reaction by slowly adding cold 20% 10 aq KH_2PO_4 (35 mL), followed by cold H_2O (300 mL); let stir 15 min (temperature rose to -7°C). Poured into 2-L separatory funnel and extracted with hexanes (500 mL). Washed the organic extract with cold 10% aq KH_2PO_4 (3x300 mL) and saturated aqueous NaCl (300 mL). Dried the 15 organic over anhydrous Na_2SO_4 , filtered and concentrated in vacuo to give yellow oil. Purification by SiO_2 flash chromatography (10cm x 20 cm column) with 35:65 EtOAc/Hexanes afforded the title compound as a white solid (22.2 g, 0.0859 mol, 73%):

20

^1H NMR (CDCl_3) δ 1.267-1.465 (m, 16H), 1.802 (dd, $J=12.7$ Hz, 2.2 Hz, 1H), 2.290-2.464 (m, 2H), 4.314 (d, $J=18.4$ Hz, 2H), 9.555 (d, $J=1.3$ Hz, 1H).

25


H.



To a cooled (-78°C) solution of compound F (2.02 g, 4.19 mmol) in anhydrous THF (30 mL) under argon was 30 slowly added a 2.5 M THF solution of n-butyllithium (2.1 mL) over a period of 40 minutes. The temperature was maintained below -75°C during the addition. After the

addition was complete, the reaction mixture was stirred for another 40 minutes at -78°C. A solution of compound G (2.2 g, 8.52 mmol) in THF under argon was cannulated into the phosphonate mixture at -78°C. After the addition was 5 complete, the reaction was stirred for 1 hour at -78°C. The reaction was then warmed to -10°C and stirred for 1 hour and then stirred at room temperature for an additional hour. The mixture was quenched with saturated ammonium chloride solution (5mL) and extracted with ethyl 10 acetate (60 mL x 3). The combined organic layers were washed with water (10mL) and brine (10mL); then dried over sodium sulfate (Na_2SO_4) and filtered. The filtrate was concentrated *in vacuo*. Flash chromatography using 5% to 10% ethyl acetate in hexane as eluent afforded 1.48 g 15 (60% yield) of compound H as a white solid. ESI-LC/MS $(\text{M}+\text{H})^+ = 586$; m.p. 148-149°C.

I.




20

To a cooled (0°C) solution of compound H (500 mg, 0.854 mmol) in anhydrous CH_2Cl_2 (12mL) under argon was slowly added trifluoroacetic acid (987 mL, 12.82 mmol). After the addition was complete, the reaction mixture was 25 allowed to stirred at 0°C for 10 minutes and at room temperature for 3 hours and then the solvent was removed *in vacuo*. The reaction mixture was quenched with phosphate solution (pH 7.5, 12 mL) and extracted with CH_2Cl_2 (20 mL x 2). The combined organic layers were 30 washed with brine (10mL), dried over sodium sulfate (Na_2SO_4), and filtered. The solvent was removed *in vacuo*. Flash silica gel chromatography using 30% to 50% ethyl

acetate in hexane as an eluent afforded 331mg (80% yield) of compound I as a white powder. ESI-LC/MS $(M+H)^+=588$; m.p. = 199-200°C.

5

J.



To a solution of compound I (316 mg, 0.671 mmol) in anhydrous THF (6mL) at room temperature was added an aqueous solution of sodium hydroxide (1N NaOH, 839 μ L, 0.839 mmol). The reaction was stirred at room temperature for 10 minutes. The solvent was removed *in vacuo* and taken up in water (5mL). The solution was chromatographed on SP-207 resin eluting with water, followed by 25%-40% acetonitrile in water. The desired fractions were stripped, redissolved in water and lyophilized to give title compound (308 mg, 94% yield) as a white solid. ESI-LC/MS $(M+H)^+=490$; ESI-MS $(M+H)^+ = 490$;

10 ^1H NMR (DMSO-D6; 400MHz) δ 0.97-1.01 (m, 1H), 1.24-1.46 (m, 7H), 1.73-1.78 (m, 1H), 1.93-2.05 (m, 5H), 2.49-2.52 (m, 2H), 3.40-3.53 (m, 2H), 4.03-4.08 (m, 1H), 5.34 (dd, 1H, J = 5.72, 10.56 Hz), 6.29 (d, 1H, J = 16.24 Hz), 7.21-7.19 (m, 5H), 7.32-7.42 (m, 2H), 7.71 (d, 1H, J = 7.48Hz);

20 ^{13}C NMR (DMSO-D6, 400MHz) δ 175.6, 162.5, 161.3, 160.1, 154.2, 147.8, 140.5, 138.8, 134.5, 130.7, 130.5, 129.6, 128.5, 128.1, 126.3, 115.1, 114.9, 68.2, 66.6, 43.7,

25 43.3, 38.4, 32.3, 30.6, 30.1, 26.4, 24.8, 22.8, 22.7.


30 Anal. Calcd for $C_{30}H_{32}NO_4FNa \bullet 0.9 H_2O$: C, 68.14; H, 6.44;

N, 2.65; F, 3.59; Na, 4.35. Found: C, 67.79; H, 5.97; N, 2.51; F, 3.86; Na, 4.83.

Example 2A


5 Alternate Procedure for Example 2 Part H Compound

H(1) .



To a stirred solution of Example 2 Part E compound
10 (3.34 g, 7.9 mmol) in toluene (40 mL) was added O-ethyl
diphenylphosphinate (2.65 g, 11.5 mmol) in one portion.
The reaction was heated to reflux for 2h, then cooled to
room temperature. The white precipitate was collected
via filtration and washed with heptane. The residue was
15 dried *in vacuo* overnight to give title compound as a
white solid, 4.3 g, 99% yield, mp 264-265°C.

H(2) .




20 To part H(1) compound (109 mg, 0.2 mmol) in 25 mL
2-necked round bottom flask (flame-dried and fitted with
an argon-filled balloon, vacuum take-off and a
thermocouple) was added 0.5 mL of DMPU (distilled over
25 CaH₂ under reduced pressure, stored with 4A molecular
sieves). The resulting slurry was warmed while stirring
until becoming a clear solution, which was diluted with
THF (1.5 mL). The reaction mixture was evacuated and
purged three times with argon, then cooled to -78°C. To

the cooled reaction mixture was added dropwise 0.42 mL of a 0.5 M solution of LDA in THF¹ (0.21 mmol). An amber colored solution formed. After stirring at -78°C for 30 minutes, a solution of Example 2 Part G aldehyde (67 mg, 5 0.26 mmol) in THF (0.5 mL) was added via a syringe. After addition, the resulting yellow solution was stirred at -78°C for 30 minutes, then at 0°C for 1 hour before quenched with an aqueous solution of ammonium chloride. The reaction mixture was extracted three times with ethyl 10 acetate (10 mL). The organic extracts were combined, washed with water and brine, dried (MgSO_4) and evaporated. The crude product was purified using flash chromatography on silica gel eluting with 5% EtOAc/hexane. The desired fractions were pooled and concentrated, and the collected 15 residue dried *in vacuo* overnight to give Part H(2) compound as a white foam, 80 mg (68% yield).


¹A stock solution of 0.5 M LDA in THF was prepared from diisopropylamine (redistilled, Aldrich) and 2.5 M of BuLi 20 in hexane (Aldrich) following the usual procedures and stored at -20°C.

Example 3




25

A.



To a solution of Example 2 Part H compound (500 mg,
 5 0.854 mmol) in a mixture of MeOH and EtOH (10 mL) was
 added 10% Palladium/C (100 mg) and purged with hydrogen
 (H_2). The reaction mixture was then stirred at 55 psi
 under hydrogen for 2 hours. Upon the completion of the
 reaction, the catalyst was filtered and the solvent was
 10 removed *in vacuo* to afford 500mg (99% yield) of the
 product as a white foam. ESI-LC/MS ($M+H$)⁺=588.

B.




15

To a cooled (0°C) solution of Part A compound
 (450mg, 0.766 mmol) in anhydrous CH_2Cl_2 , (9mL) under argon
 was slowly added trifluoroacetic acid (886 mL, 12.5
 mmol). After the addition was complete, the reaction
 20 mixture was allowed to stirred at 0°C for 10 minutes and
 at room temperature for 3 hours and then the solvent was
 removed *in vacuo*. The reaction mixture was quenched with
 phosphate solution (pH 7.5, 12 mL) and extracted with
 CH_2Cl_2 (20 mL x 2). The combined organic layer was washed
 25 with brine (saturated NaCl solution, 10mL), dried over
 sodium sulfate (Na_2SO_4) and filtered. The solvent was

removed in *vacuo*. Flash silica gel chromatography using 30% to 50% ethyl acetate in hexane as an eluent afford 330mg (91% yield) part B compound as a white powder. ESI-LC/MS ($M+H$)⁺=474, MP (°C) = 253-254.

5

C.



To a solution of part B compound (330mg, 0.698 mmol) in anhydrous THF (8mL) at room temperature was added an aqueous solution of sodium hydroxide (1N NaOH, 872 μ l, 0.872 mmol). The reaction was stirred at room temperature for 10 minutes. The solvent was removed in *vacuo* and taken up in water (5mL). SP-207 resin bound chromatography using water, followed by 20% to 40% acetonitrile in water as the eluent afford 315 mg (92% yield) of Part C compound as a white lyophilicate. The SP-207 resin was pre-washed with saturated sodium bicarbonate solution (NaHCO₃, 50 mL) followed by saturated sodium chloride solution (NaCl, 50 mL), and water (200 mL).

ESI-LC/MS ($M+H$)⁺=492, ESI-MS ($M+H$)⁺ = 492;

¹H NMR (DMSO-D6; 400MHz) δ 1.05-1.09 (m, 1H), 1.23-1.29 (m, 8H), 1.35-1.44 (m, 2H), 1.70-1.78 (m, 1H), 1.90-1.98 (m, 6H), 2.25-2.35 (m, 1H), 2.45-2.55 (m, 1H), 3.36-3.40 (m, 1H), 3.62-3.65 (m, 1H), 4.70 (s, 1H), 7.25-7.41 (m, 7H), 7.67 (d, 1H, J = 7.48Hz);


30

¹³C NMR (DMSO-D6, 400MHz) δ 175.8, 162.4, 160.6, 160.0, 155.0, 146.8, 141.0, 140.3, 138.9, 134.7, 131.2, 130.9,

129.5, 128.8, 128.3, 126.3, 68.6, 65.6, 44.7, 44.3, 40.0,
32.6, 31.1, 30.6, 26.3, 22.2.

Following the procedure of Examples 1 to 3 the
5 following compounds may be prepared.


Examples 4 to 18




10

where Y is as set out below

Example 4



Example 5




Example 6




15


Example 7






Example 8






Example 9









Example 10Example 11Example 12

5







Example 13Example 14Example 15




10

Example 16Example 17Example 18





Example 19Example 20Example 21

5

Example 22Example 23Example 24Example 25Example 26Example 27

Example 28Example 29Example 30


5

Example 31Example 32Example 33Example 34

10


It will be appreciated that the compounds of Examples 1 to 34 may also be converted to corresponding lactones and/or salts thereof.

15 With respect to Examples 35 to 38, please refer to Scheme 6.

Example 35Preparation of Pyridine Aldehyde (18) (Scheme 6)

5

A.



To a mixture of 4-fluoro-benzaldehyde (935.8 g,
 10 7.54 moles) and methyl isobutyryl acetate (1087 g, 7.54
 moles) was added piperidine (64.2 g, 0.75 mol), followed
 by acetic acid (22.6 g, 0.38 mol). The mixture was
 heated to 80 to 85° C for about 2 hours. 16 Liters (4 x
 15 4L) of toluene was added and mixed with the reaction
 mixture. The toluene was removed using a rotavapor (50-
 65° C/20-90 torr), leaving a yellow oil. The yellow oil
 was dissolved in 5L MTBE and washed with:

1 x 3L HCl (0.5N)


1 x 3L NaHCO₃ (saturated soln.)

20 1 x 3L DI water

The MTBE was evaporated off. Thereafter, 1.5L of
 MTBE was added and the mixture evaporated to remove water
 to afford about 1780 g (yield 88%) of title compound as a
 yellow oil.

25


B.



- 5 To 7.35 L NaHMDS (7.35 moles, 1.05 eq) under N₂ (cooled down between -72 to -65°C) was added a THF (6 L) solution of 1-benzosuborone (1177 g, 7.35 moles, 1.05 eq). The reaction temperature was maintained below -50°C during the addition. The reaction was then stirred at -
- 10 between -72 to -65°C for 1 hour and a solution of compound A (1751.5g, 7.0 moles, in 6 L THF) was slowly added to the reaction while keeping the temperature below -50°C. After the addition was complete, the reaction was stirred for 2-3 hours between -72 to -65°C. The reaction
- 15 was quenched with HOAc (1.4L) between -72 to -50°C. The mixture was allowed to reach RT and saturated ammonium chloride solution (NH₄Cl, 15L) was added plus 7L DI-water, and the mixture agitated for 5-10 min. The aqueous layer was extracted with 1 x 8L MTBE. The combined organic
- 20 layers were washed with water (2 x 9L) and brine (1 x 9L), then dried. The solvent was removed to afford crude compound B (3.08 kg). The crude compound B was used directly in the next step.

25

C.



- To a solution of the crude compound B (3078 g) in aqueous HOAc (16L) was added ammonium acetate (1446 g), followed by cupric acetate monohydrate (1859 g). The reaction was refluxed between 120 to 124°C for 12-15


hours. Approximately 90% of the acetic acid was evaporated to produce a green slurry. The slurry was then mixed with 14L MTBE.

The resulting solution was filtered through a 5 celite pad (177g celite in a 7" x 8", WxH, funnel) and the cake washed with 16L MTB. The organic phase was washed with:

- 2 x 9 L DI-water, pH of combined wash=4.2
- 2 x 3 L NaHCO₃, pH of the combined wash=6.4
- 10 - 1 x 9 L DI-water, pH=6.0.

The solvent was evaporated to produce a black oil (2883 g). 2.5 L of methanol was added and the mixture agitated for approximately 2-3 h. The product was filtered and washed with 2 L of cold methanol (-10 to 15 0°C). The product was dried at 40-50°C/~20" of Hg to produce an off-white solid, 793 g, HPLC AP=97.8. Yield = 27%.

D.




20


To a 500 mL round bottom flask equipped with a magnetic stirrer and a nitrogen inlet was charged Part C compound (17) (Scheme 6) (50.0g, 128.4 mmol) and toluene (170 mL). The mixture was stirred at 20-25°C until a clear solution was obtained. A solutin of 65% Red-Al in toluene (57.8 mL, 192.6 mmol) was added and the reaction mixture was heated to 80°C until complete as determined by HPLC. The reaction mixture was cooled to ~20°C and 25 quenched by pouring it into cold (0-5°C) 20% HCl (495 mL). Phases were separated and the spent toluene phase 30 was discarded. The pH of the aqueous phase was adjusted

from <0 to 4-5 with 10N NaOH. Ethyl acetate (500 mL) was added and the pH adjustment continued to 7-8. The phases were separated. The aqueous phase was extracted with additional ethyl acetate (2 x 500 mL). The combined rich
5 ethyl acetate solution was washed with water (3 x 250 mL) and concentrated under reduced pressure to ~465 mL. This solution was carried through to the next oxidation step.

The rich ethyl acetate solution was charged from above into a three neck 1-L flask equipped with
10 mechanical stirring, temperature controller, and addition funnel and cooled to 0-5°C. To the slurry, potassium bromide (1.53 g, 12.8 mmol) and TEMPO (2,2,6,6-tetramethyl-1-piperidinyloxy) (0.20 g, 1.28 mmol) were added. The pH of NaOCl (sodium hypochlorite) solution
15 (212.1 mL) was adjusted to ~9.1 and added to the slurry at a rate such that the temperature remained at 0-5°C. Stirring was continued at 0-5°C until the reaction was complete as determined by HPLC. The aqueous phase was extracted with EtOAc (2 x 200 mL). The combined rich
20 organic phase was washed with a 1:1 solution of sat. aq. Na₂S₂O₃ (sodium thiosulfate) (75 mL) and water (75 mL) followed by wash of the rich organic phase with 1N NaOH (250 mL). The rich organic phase was washed with water (250 mL) and concentrated to ~100 mL under reduced
25 pressure. Isopropanol (IPA) (400 mL) was added and the resulting mixture was heated to reflux (80-85°C). The solution was distilled to a volume of ~250 mL. Water (50 mL) was added and the crystal slurry was stirred at 70-80°C for 1 h then allowed to cool to 20-25°C over at least
30 1 h. The slurry was held at 20-25°C for at least 1 h before collecting the solid by filtration on a Buchner funnel. The cake was washed with cold (0°C) IPA/water (4:1) (2 x 50 mL) and dried to a constant weight under vacuum at 40°C to afford 41.5 g (90%) of title aldehyde
35 as a white crystalline solid.


Example 36

5

A. Preparation of Sulfide (15)

To a 250 mL flask was charged Kaneka alcohol (12) (Scheme 6) (10.0 g, 38.41 mmol), methylene chloride (100 mL), and triethylamine (11.75 mL, 84.51 mmol) and cooled to -30°C . Triflic anhydride (7.11 mL, 42.25 mmol) was added via a syringe at a rate to maintain the temperature at -35 to -25°C, ~15 min. The reaction mixture was stirred at -30°C for ~30 min and checked for disappearance of Kaneka alcohol by TLC. A slurry of 1-phenyl-1H-tetrazole-5-thiol (7.19 g, 40.34 mmol) in methylene chloride (50 mL) was added to the triflate solution. After the reaction was complete, water (100 mL) was added and the mixture was stirred for ~5 min. The phases were separated and the aqueous phase was discarded. The rich organic phase was washed with water (100 mL) for ~5 min and phases separated. The rich organic phase was washed with saturated NaHCO₃ (100 mL) for ~15 min and phases separated. The rich organic phase was concentrated to ~50 mL. The solution was taken to the next step for further transformation.


B. Preparation of Sulfone (16)



- IPA (150 mL) was added to the Part A sulfide solution from the above step. The solution was cooled to 0-5°C. To the stirred solution of sulfide, a solution of $(\text{NH}_4)_6\text{MO}_7\text{O}_{24} \cdot 4\text{H}_2\text{O}$ (ammonium heptamolybdate tetrahydrate) (4.75 g, 3.84 mmol) in 30% H_2O_2 (hydrogen peroxide) was added dropwise during ~15 min, maintaining the temperature of the solution at 0-5°C. The conversion of sulfide to sulfone was monitored by HPLC ~24 h. After completion of the reaction, methylene chloride was distilled out. The pot temperature was maintained at not more than 25°C. The crystal slurry was distilled to a volume of ~230 mL with IPA and the resulting slurry was stirred for at least 1 h at 20-22°C. The solid was collected by vacuum filtration, the cake washed with IPA/water (4:1, 25 mL) followed by drying under vacuum at 40°C to constant weight affording 12.8 g (74%) of the title sulfone as a white crystalline solid.

Example 37

Preparation of Olefin (19)



25

An N_2 purged 250 mL 3-neck rb flask was charged with Example 35 pyridine derivative (18) (5.0 g, 13.9 mmol), Example 36 sulfone (16) (6.92 g, 15.3 mmol) and THF (75 mL). The stirred solution was cooled to -74 to -78°C.


Slowly a 1M solution of LiHMDS (lithium bis(trimethylsilyl)amide) (15.3 mL, 15.3 mmol) in THF was charged at a rate such that the temperature remained between -70 and -78°C. After addition of the base was 5 complete, the reaction mixture was warmed to ~-45°C over ~15 minutes. The stirred reaction was quenched at -70°C by slow addition of sat. aq. NH₄Cl (7.5 mL) solution and water (38 mL). The dry ice bath was removed and the solution was warmed to 20-25°C from the reaction mixture.

10 Ethyl acetate (50 mL) was added, the mixture agitated, and layers separated. The organic layer was washed with saturated sodium bicarbonate solution (2 x 38 mL) followed by brine (25 mL) and concentrated to a volume of 50 mL. Acetonitrile (50 mL) was added and the solution

15 was concentrated to a volume of 50 mL. This step was repeated. Water (~5-6 mL) was slowly added to the hot solution (60-70°C) until the cloud point was reached. The thin slurry was held for 30 min at high temperature and then slowly cooled over several hours with stirring.


20 The product was filtered, cake was washed with a 5:1 mixture of acetonitrile and water, and dried to afford 7.5 g (91%) of the title compound as a white crystalline material.

25

Example 38Preparation of the final compound as arginine salt (Ib⁹)


30 To a 3.0-liter round bottom flask equipped with a mechanical stirrer, a thermometer, and a septa was charged Example 37 trans olefin (19) (92.0 g, 157 mmol) and THF (600 mL) at ambient temperature. With stirring,

to the resulting clear sight yellow solution was added 6N HCl (aq. 74.6 mL, 447 mmol) at ambient temperature to form (20)




5

The reaction mixture was stirred for 5.0-6.0 h followed by addition of 2 N NaOH (aq. 389 mL, 777 mmol) to form a light yellow suspension. Agitation was maintained at ambient until reaction (saponification of (20)) was
10 judged complete by an in-process HPLC assay. THF was evaporated on a rotary evaporator at about 45°C. The white slurry residue was diluted with 1000 mL of water and was extracted with MTBE (methyl t-butyl ether) (230 mL x 2). After separating the MTBE layer, the aqueous
15 layer containing (21)



was transferred to a 5.0-liter round bottom flask equipped with a mechanical stirrer, a thermometer, and a septa. While temperature was controlled at <29°C, 1 N HCl (aq) was added to the above aqueous layer until the pH=6.94. Subsequently, 330 mL of ethyl acetate was added to the aqueous layer followed by charging more 1 N HCl (aq) until pH=2.82. After separating and saving the ethyl acetate layer, the aqueous layer was extracted with

ethyl acetate (330 mL x 3). The combined ethyl acetate layers containing acid Ib⁸ of the invention



- 5 were washed with 50% brine (265 mL), brine (427 mL), separated and mixed with a suspension of L-arginine (27.4 g, 157 mmol) in ethanol (276 mL) and water (138 mL). The mixture was evaporated to dryness under reduced pressure at ca 45-50°C. To the resulting white solid were added
 10 ethyl acetate (450 mL), ethanol (316 mL), and water (145 mL) followed by heating the white suspension to 50°C. Another 36.7 mL of water was added to dissolve all solids at 56°C; subsequently 1720 mL of ethyl acetate was added to the hot solution to initialize the crystallization.
 15 The white suspension was stirred at 50°C for 1.5 h and at ambient for 13 h. After filtration, the crystalline solid was washed with 143 mL of a mixture of EtOAc (200 mL), EtOH (12 mL) and H₂O (6 mL) and was dried in vacuo at 40-50°C for 24 h. The title product obtained as a
 20 white solid weighed 78.9 (g). Yield, 75.7%. [α]²⁵_D=+23.0 (c 0.31, CH₃CN:H₂O, 1:1, v/v).

¹H NMR (CD₃OD): δ 7.74 (dd, J=2.5 Hz, J'=1.0 Hz, 1H), 7.41 (dt, J=7.0 Hz, J'=6.1 Hz, 1H), 7.37 (dt, J=7.3 Hz, J'=1.4 Hz, 1H), 7.27 (d, J=7.2 Hz, 1H), 7.22 (dd, J=15.4 Hz, J'=7.0 Hz, 2H), 7.20 (d, J=7.0 Hz, 2H), 6.45 (d, J=16.5 Hz, 1H), 5.43 (dd, J=16.5 Hz, J'=6.5 Hz, 1H), 4.24 (q, J=6.5 Hz, 1H), 3.79 (m, 1H), 3.55-3.50 (m, 2H), 3.23 (m, 2H), 2.62 (t, J=7.2 Hz, 2H), 2.31-2.21 (m, 2H), 2.16 (t, J=6.8 Hz, 2H), 2.05 (m, 2H), 1.87 (q, J=7.0 Hz, 2H), 1.74

(m, 2H), 1.57 (m, 1H), 1.34 (d, J=6.8 Hz, 6H), 1.31 (m, 1H).

¹³C NMR (CD₃OD): δ 180.1, 174.7, 164.5, 163.1, 162.5,
5 158.7, 157.8, 149.1, 141.9, 141.0, 140.8, 136.4, 132.6,
132.3, 131.6, 130.5, 130.1, 129.7, 129.2, 127.6, 126.6,
116.3, 116.0, 71.5, 68.0, 55.6, 45.0, 41.9, 34.2, 33.1,
32.2, 29.6, 27.7, 25.8, 22.5.


10 MS: calc'd for C₃₆H₄₆FN₅O₆ (M⁺ + H) 490 and 175, found
490 and 175.

IR (KBr): 3341, 3200, 3070, 2960, 2934, 2860, 1670,
1629, 1602, 1580, 1509, 1465, 1450, 1397, 1357, 1221,
15 842, 766, 740 cm⁻¹.


Anal. Calc'd for C₃₆H₄₆FN₅O₆: C, 65.14, H, 6.98, N, 10.55.
Found C, 65.15, H, 6.97, N, 10.53.

What is claimed is:

1. A compound having the structure



5 wherein



n is 0 or 1;

x is 0, 1, 2, 3 or 4;

10 y is 0, 1, 2, 3 or 4, provided that at least one of x and y is other than 0; and optionally one or more carbons of $(CH_2)_x$ and/or one or more carbons of $(CH_2)_y$ together with additional carbons form a 3 to 7 membered spirocyclic ring;

15 R_1 and R_2 are the same or different and are independently selected from alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl or cycloheteroalkyl;

R_3 is H or lower alkyl;

20 R_4 is H, halogen, CF_3 , hydroxy, alkyl, alkoxy, alkanoylamino, aroylamino or cyano;

R_7 is H or lower alkyl;

and represents a single bond or a double bond (which may be cis or trans);

and pharmaceutically acceptable salts thereof (when R₃ is H), esters thereof, prodrug esters thereof, and all stereoisomers thereof.

5 2. The compound as defined in Claim 1 wherein ~~is a double bond which is trans.~~

3. The compound as defined in Claim 1 wherein R₁ is aryl,

10 R₂ is alkyl or cycloalkyl or aryl;

R₄ is H;

n is 0;

x is 3;


y is 0; and

15 ~~is a trans double bond, in the form of a free acid, an alkali metal salt, or an alkaline earth metal salt, or an amino acid salt.~~

4. The compound as defined in Claim 3 wherein R₁ is 4-fluorophenyl, 4-fluoro-3-methylphenyl, or 3,5-dimethylphenyl; and

R₂ is isopropyl, t-butyl or cyclopropyl.


5. The compound as defined in Claim 1 having the
25 structure



or an alkali metal salt, or an alkaline earth metal salt, or an amino acid salt, or an acid addition salt via the pyridine of the corresponding δ lactone,


wherein R₅ and R₆ are the same or different and are independently selected from H, halogen or alkyl and R₂ is alkyl or cycloalkyl.

- 5 6. The compound as defined in Claim 1 having the structure



;

or




10

wherein R₃ is H or an alkali metal, alkaline earth metal, amino acid salt, or other pharmaceutically acceptable salt, or the internal lactone thereof, in the form of its calcium salt, sodium salt or arginine salt.

15

7. A compound of the structure



wherein R₃ is H or an alkali or alkaline earth metal ion or an amino acid, or the internal lactone thereof, in the form of its sodium salt, calcium salt or arginine salt.

5 8. A pharmaceutical composition comprising a compound as defined in Claim 1 and a pharmaceutically acceptable carrier therefor.

9. A pharmaceutical combination comprising the HMG
10 CoA reductase inhibitor compound as defined in Claim 1 and one or more hypolipidemic agents or lipid-lowering agents, or lipid agents, or lipid modulating agents, and/or one or more other types of therapeutic agents including antidiabetic agents, anti-obesity agents,
15 antihypertensive agents, platelet aggregation inhibitors, anti-dementia agents, anti-Alzheimer's agents, anti-osteoporosis agents, and/or hormone replacement therapeutic agents, and/or other cardiovascular agents (including anti-anginal agents, anti-arrhythmic agents,
20 anti-atherosclerosis agents, anti-inflammatory agents, anti-arthritis agents, anti-platelet agents, anti-heart failure agents), anti-cancer agents, anti-infective agents, hormone replacement agents, growth hormone secretagogues, selective androgen receptor modulators,
25 and/or immunomodulatory agents.

10. The combination as defined in Claim 9 wherein the hypolipidemic agent or lipid-lowering agent or other lipid agent or lipid modulating agent or anti-
30 atherosclerotic agent, which is employed comprises 1,2,3 or more MTP inhibitors, HMG CoA reductase inhibitors, squalene synthetase inhibitors, fibric acid derivatives, PPAR α agonists, PPAR dual α/γ agonists, PPAR δ agonists, ACAT inhibitors, lipoxygenase inhibitors, cholesterol
35 absorption inhibitors, ileal Na⁺/bile acid cotransporter inhibitors, upregulators of LDL receptor activity, cholesteryl ester transfer protein inhibitors, bile acid

sequestrants, or nicotinic acid and derivatives thereof, ATP citrate lyase inhibitors, phytoestrogen compounds, an HDL upregulators, LDL catabolism promoters, antioxidants, PLA-2 inhibitors, antihomocysteine agents, HMG-CoA synthase inhibitors, lanosterol demethylase inhibitors, or sterol regulating element binding protein-I agents; wherein the antidiabetic agent which may be optionally employed is 1,2,3 or more antidiabetic agents or antihyperglycemic agents including insulin

5 10 15 20 25 30 35

secretagogues or insulin sensitizers, which may include biguanides, sulfonyl ureas, PTP-1B inhibitors, aldose reductase inhibitors, glucosidase inhibitors, PPAR γ agonists, PPAR α agonists, PPAR δ antagonists or agonists, aP2 inhibitors, PPAR α/γ dual agonists, dipeptidyl peptidase IV (DP4) inhibitors, SGLT2 inhibitors, glycogen phosphorylase inhibitors, and/or meglitinides, insulin, and/or glucagon-like peptide-1 (GLP-1) or a mimetics thereof; wherein the other type of therapeutic agent which may be optionally employed is 1, 2, 3 or more of an anti-obesity agent which is a beta 3 adrenergic agonist, a lipase inhibitor, a serotonin (and dopamine) reuptake inhibitor, an aP2 inhibitor, a thyroid receptor beta drug, an anorectic agent, a PTP-1B inhibitor, a CCKA agonist, a neuropeptide Y antagonist, a melanocortin-4-receptor agonist, a PPAR modulator which is a PPAR γ antagonist, PPAR α agonist, and/or PPAR δ antagonist, a leptin inhibitor such as a leptin receptor activator, a fatty acid oxidation upregulator or inducer; wherein the lipid modulating agent is an MTP inhibitor, an HMG CoA reductase inhibitor, a squalene synthetase inhibitor, a fibric acid derivative, an upregulator of LDL receptor activity, a lipoxygenase inhibitor, or an ACAT inhibitor and the other lipid agent is a cholesteryl ester transfer protein inhibitor; wherein the antihypertensive agent employed is an ACE inhibitor, angiotensin II receptor antagonist, NEP

inhibitor, a NEP/ACE inhibitor, a calcium channel blocker, a T-channel calcium antagonist, a β -adrenergic blocker, a diuretic, a α -adrenergic blocker, a dual action receptor antagonist (DARA), or a heart failure drug.

11. The combination as defined in Claim 10 wherein the antidiabetic agent is 1, 2, 3 or more of metformin, glyburide, glimepiride, glipyride, glipizide, 10 chlorpropamide, gliclazide, acarbose, miglitol, pioglitazone, troglitazone, rosiglitazone, insulin, Gl-262570, isaglitazone, JTT-501, NN-2344, L895645, YM-440, R-119702, AJ9677, repaglinide, nateglinide, KAD1129, AR-HO39242, GW-409544, KRP297, AC2993, LY315902, 15 P32/98 and/or NVP-DPP-728A;

wherein the anti-obesity agent is orlistat, ATL-962, AJ9677, L750355, CP331648, sibutramine, topiramate; axokine, dexamphetamine, phentermine, phenylpropanolamine, and/or mazindol, P57 or CP-644673 20 (Pfizer);

wherein the lipid modulating agent is pravastatin, lovastatin, simvastatin, atorvastatin, cerivastatin, fluvastatin, pitavastatin, rosuvastatin, fenofibrate, gemfibrozil, clofibrate, avasimibe, TS-962, MD-700, 25 cholestagel, niacin, and/or LY295427;

wherein the antihypertensive agent is an ACE inhibitor which is captopril, fosinopril, enalapril, lisinopril, quinapril, benazepril, fentiapril, ramipril or moexipril;

30 an NEP/ACE inhibitor which is omapatrilat, gemopatrilat, or CGS 30440;

an angiotensin II receptor antagonist which is irbesartan, losartan or valsartan;

35 amlodipine besylate, prazosin HCl, verapamil, nifedipine, nadolol, propranolol, or clonidine HCl, carvediol, atenolol, hydrochlorothiazide, torasemide, furosemide, spironolactone or indapamide;


- wherein the platelet aggregation inhibitor is aspirin, clopidogrel, ticlopidine, dipyridamole, ifetroban, abciximab, tirofiban, eptifibatide, or anagrelide;
- 5 wherein the other therapeutic agent is an anti-Alzheimer's agent or anti-dementia agent, which is tacrine HCl (Cognex®), donepezil (Aricept®), a Y-secretase inhibitor, a β-secretase inhibitor and/or antihypertensive agent;
- 10 an antiosteoporosis agent, which is parathyroid hormone, a bisphosphonate, alendronate, a Ca receptor agonist or a progestin receptor agonist;
 a hormone replacement therapeutic agent, which is a selective estrogen receptor modulator (SERM);
- 15 a tyrosine kinase inhibitor;
 a selective androgen receptor modulator;
 an antiarrhythmic agent, which is a β-blocker, or a calcium channel blocker, or an α-adrenergic blocker;
 coenzyme Q sub. 10;
- 20 an agent that upregulates type III endothelial cell nitric acid syntase;
 a chondroprotective compound which is polysulfated glycosaminoglycan (PSGAG), glucosamine, chondroitin sulfate (CS), hyaluronic acid (HA), pentosan polysulfate (PPS), doxycycline or minocycline;
- 25 a cyclooxygenase (COX)-2 inhibitor, which is Celebrex® (Searle) or Vioxx® (Merck) or a glycoprotein IIa/IIIb receptor antagonist;
 a 5-HT reuptake inhibitor;
- 30 a growth hormone secretagogue;
 an anti-atherosclerosis agent;
 an anti-infective agent, or an immunosuppressant for use in transplantation, or an antineoplastic agent.
- 35 12. The combination as defined in Claim 10 wherein the HMG CoA reductase inhibitor compound is in combination with an ACE inhibitor or a NEP/ACE inhibitor.

13. The combination as defined in Claim 12 wherein
the HMG CoA reductase inhibitor compound is in
combination with an ACE inhibitor which is rampipril;
- 5 wherein the HMG CoA reductase inhibitor is in
combination with a NEP/ACE inhibitor which is omapatrilat
or gemopatrilat;
- wherein the HMG CoA reductase inhibitor is in
combination with a platelet aggregation inhibitor.
- 10
14. The combination as defined in Claim 13 wherein
the platelet inhibitor is clopidogrel, or aspirin or a
combination of clopidogrel and aspirin.
- 15 15. A method of inhibiting cholesterol biosynthesis
or lowering blood serum cholesterol levels and/or
modulating blood serum cholesterol levels, lowering LDL
cholesterol and/or increasing HDL cholesterol, or
treating dyslipidemia, mixed dyslipidemia, LDL Pattern B,
20 LDL Pattern A, hyperlipidemia, hypercholesterolemia, hypo
 α -lipoproteinemia, hyperlipoproteinemia or
hypertriglyceridemia, and other aberrations of
apolipoprotein B metabolism, or reducing levels of Lp(a),
or treating or preventing other cholesterol-related
25 diseases, or treating or preventing or reversing
progression of atherosclerosis, or preventing or treating
Alzheimer's disease, or preventing or treating
osteoporosis and/or osteopenia, or reducing inflammatory
markers, reducing C-reactive protein, or preventing or
30 treating low grade vascular inflammation, or preventing
or treating stroke, or preventing or treating dementia,
or preventing and treating coronary heart disease, and
primary and secondary prevention of myocardial
infarction, or preventing or treating stable and unstable
35 angina, or primary prevention of coronary events, or
secondary prevention of cardiovascular events, or
preventing or treating peripheral vascular disease,




preventing or treating peripheral arterial disease, or preventing or treating acute vascular syndromes, or preventing or reducing the risk of undergoing myocardial revascularization procedures, or preventing or treating 5 microvascular diseases such as nephropathy, neuropathy, retinopathy and nephrotic syndrome, or preventing or treating hypertension, preventing or treating Type I diabetes, Type 2 diabetes, and related diseases, insulin resistance, hyperglycemia, hyperinsulinemia, elevated 10 blood levels of fatty acids or glycerol, obesity, LDL Pattern B, LDL Pattern A, Syndrome X, diabetic complications, dysmetabolic syndrome, and related diseases, and sexual dysfunction, preventing and treating malignant lesions, premalignant lesions, gastrointestinal 15 malignancies, liposarcomas and epithelial tumors, cancer-induced asthenia (fatigue), irritable bowel syndrome, Crohn's disease, gastric ulceritis, and gallstones, and HIV infection, drug-induced lipodystrophy, and proliferative diseases, improving coagulation 20 homeostasis, reducing PAI-1 activity, reducing fibrinogen, and/or reducing platelet aggregation, and/or improving endothelial function, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of a compound as 25 defined in Claim 1.

16. A method for treating cholesterol related diseases, diabetes and related diseases, cardiovascular diseases, cerebrovascular diseases, which comprises 30 administering to a mammalian species in need of treatment a therapeutically effective amount of a combination of a compound as defined in Claim 1 and a hypolipidemic agent, and/or lipid modulating agent and/or antidiabetic agent and/or cardiovascular agent, cerebrovascular agent, 35 and/or other type of therapeutic agent, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of such combinations.




17. A compound having the structure



5 wherein R₁ and R₂ are the same or different and are independently selected from alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl or cycloheteroalkyl; Q is



18. The compound as defined in Claim 17 having the following structures:



(W=aryl, alkyl or alkoxy)

